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ABSTRACT 
The fetal origin of disease hypothesis asserts that childhood predisposition to disease can 
be conditioned by intrauterine factors which, thus far, have not been well characterized. In 
malaria-endemic areas, fetuses of women infected with the malaria parasite Plasmodium 
falciparum (Pf) can be exposed to Pf antigens in utero during the second and third trimesters of 
gestation. The present dissertation comprises pioneer studies investigating the timing of 
acquisition antibody responses to Pf antigens in utero and the influence of the amount Pf antigen 
to which the fetus is exposed, on susceptibility to malaria during the first year of life. Our data 
show that the human fetus is not immunologically hyporesponsive as specific IgM to a wide 
breadth of Pf antigens were made by fetal B cells as early as 22 weeks of gestation and fetal B 
cells were capable of class-switching from Pf IgM to Pf IgG production towards term gestation. 
We also demonstrated that exposure to low and not high amount of Pf antigens in utero is 
associated with increased susceptibility to malaria since infants born to mothers with low 
placental parasitemia had a significantly higher number of infections during the first year of life 
and shorter time to first postnatal infection compared to infants of uninfected mothers or of 
mothers with high placental parasitemia. In addition, the infants of low placental parasitemia 
mothers did not make antibodies to Pf antigens during the first postnatal infection, while infants 
of high placental parasitemia mothers made a recall antibody response characterized by boosting 
of IgG and not IgM to the Pf MSP1 antigen. The data suggest that Pf-specific memory B cells 
can be generated in utero but a threshold amount of Pf antigen exposure may be required. 
Collectively, our data confirm that prentatal factors can modify risk of malaria after birth and 
demonstrate that low placental parasitemia at birth is as a major predictor of increased 
susceptibility of infants to malaria.  Therefore, malaria control interventions during pregnancy 
should aim to eliminate and not reduce placental Pf parasitemia.  
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CHAPTER 1 
INTRODUCTION 
BURDEN OF MALARIA IN PREGNANCY AND INFANCY 
 Malaria is a mosquito-borne infectious disease caused by protozoan parasites of the genus 
Plasmodium, with P. falciparum (Pf) being the most lethal species. An estimated 3.2 billion 
people – about half of the world’s population – residing in 91 countries and territories are at risk 
of malaria. A scale-up of malaria control interventions between the years 2010 and 2015, 
resulted in a 21% decrease in the number of new malaria cases and 29% decrease in malaria 
mortality worldwide. However, the burden of malaria remains high, as over 212 million malaria 
cases and 429,000 malaria-related deaths were reported for the year 2015 by the World Health 
Organization [1].  
The burden of malaria is not evenly distributed across geographical regions and age 
groups. Children and pregnant women in sub-Saharan Africa are the most affected. For every 10 
malaria cases or deaths in 2015, 9 occurred in sub-Saharan Africa where malaria is endemic. 
More than 70% of the reported deaths occurred in children before their fifth birthday. Natural 
partial immunity to malaria is acquired slowly after repeated Pf exposures [2], thus children are 
more susceptible to Pf infection and to severe malaria disease than adults.  
Malaria during pregnancy is a major public health problem as it poses significant risks 
not just to the mother but also to her developing fetus. A combination of physiological and 
behavioral changes occurring during pregnancy place pregnant women at higher risk of Pf 
infections than their nonpregnant counterparts in the same region [3]. In addition, the 
pathogenesis of malaria in pregnancy is very unique. Unlike any other known pathogen, Pf has a 
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distinct ability to sequester in the intervillous spaces (IVS) of the placenta. This pathologic 
condition, known as placenta malaria (PM), occurs as a result of the adhesion of Pf-infected 
erythrocytes (IEs) to placental villi [4]. In pregnant women, Pf parasites express a specific 
variant of Pf-erythrocyte membrane protein 1 (PfEMP1) called VAR2CSA on the surface of IE 
which is capable of binding to chondroitin sulfate A on placental villi [5]. The sequestered IE 
stimulate resident macrophages to produce chemokines that recruit monocytes into the IVS 
leading to placental inflammation and adverse pregnancy outcomes [6–8].  PM is more common 
and more severe in primigravid women (first-time mothers) who have not yet acquired 
antibodies to VAR2CSA than in multigravid women who have acquired these antibodies as a 
result of multiple exposures to VAR2CSA during successive pregnancies [9]. 
CONSEQUENCES OF MALARIA IN PREGNANCY ON THE FETUS AND INFANT 
 Infection by Pf during pregnancy is associated with significant morbidity in the 
developing fetus, as well as in the neonate and infant. 
Placental malaria and adverse pregnancy outcomes  
 
Pregnancy outcomes associated with PM vary with the intensity of malaria transmission. 
In low transmission areas where pregnancy-related immunity to malaria is low in both 
primigravid and multigravid women, PM has been linked with spontaneous abortions and 
stillbirths [10,11]. In high transmission areas, adverse fetal comes include intrauterine growth 
retardation (small for gestational age), preterm delivery (PTD) (less than 37 complete weeks of 
gestation) and low birth weight (LBW) (less than 2,500g) [12]. In these high transmission areas, 
the poor fetal outcomes occur more frequently in primigravid women. For example, Tako and 
colleagues, showed that the adjusted odds of having a LBW baby in a high transmission setting 
of Cameroon was two times higher in primigravid compared to multigravid women [13]. 
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Multiple mechanisms contribute to PM-associated pregnancy outcomes including maternal 
anemia and dysregulation of placental angiogenesis which decrease oxygen delivery to the fetus, 
and placental inflammation with trophoblastic dysfunction which reduces nutrient transport 
across the placenta [14]. 
Exposure of the fetus to Plasmodium falciparum in utero 
When a pregnant woman is infected with Pf, her fetus can be exposed to intact IE or 
parasite products that cross the placenta. The term ‘congenital malaria’ specifically describes 
cases where live IEs are present in cord or peripheral blood of neonates. Congenital malaria is 
rare, occurring in only 0–5% of neonates in West and Central Africa [15,16]. The low prevalence 
of congenital malaria  can be explained in part by high fetal hemoglobin content at birth which is 
not conducive for Pf growth [17,18]. The mechanism by which IEs cross the placental barrier is 
largely unknown. In contrast to other parasites that cause congenital infection by invading and 
multiplying in placental trophoblastic cells (e.g., Toxoplasma gondii) and chorionic cells (e.g., 
Trypanosoma cruzi) [19], Pf does not directly infect placental tissue. It is thought that some Pf-
infected maternal red cells may gain access to the fetal circulation via microabrasions in the 
placenta during the process of labor. PM may also directly compromise the integrity of the 
placental barrier and provide a pathway for fetal infection. Crocker and collaborators, observed 
trophoblastic degradation and localized destruction of villi in placental tissue sections from 
women with placental Pf infection [20]. In a rural area of Malawi, the likelihood of congenital 
malaria was associated with high parasite density in the placenta [21]. 
Although congenital malaria is not very common, data suggest that many more babies in 
malaria-endemic regions are exposed to Pf in utero. Pf DNA and/or soluble parasite proteins 
have been detected in about 55% of newborns in sub-Saharan Africa [15,22]. Also, Metenou and 
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colleagues, demonstrated the release of Pf-specific IgG in vitro from peripheral mononuclear 
cells of 78% of Cameroonian neonates [23].  Because the mononuclear cells were isolated from 
cord blood at delivery, these neonates were primed with Pf antigens in utero. The discordance 
between the prevalence of neonates with congenital malaria and the prevalence of neonates with 
Pf-sensitized lymphocytes, suggests that other mechanisms are involved in prenatal Pf exposure 
besides intact IEs crossing through a breached placenta. Using human ex vivo placenta models, 
May and co-workers, demonstrated that Pf merozoite surface protein 1 (MSP1) crosses the 
placenta bound to MSP1-specific IgG as immune complexes [24]. Therefore, maternal IgG –  
which is physiologically transcytosed across the placenta with the help of Fc neonatal receptors 
[25–27] – provides a route for Pf antigens in the IVS to ‘hitch a ride’ into the fetal circulation.  
Prenatal origin of infant susceptibility to malaria 
Fetuses of PM-positive mothers appear to be programmed in utero for increased 
susceptibility to malaria and non-malarial infectious disease during childhood. In addition to its 
immediate adverse outcomes, PM is associated with increased number of Pf infections and 
shorter time-to-first infection in infants during the first year of life [28,29]. Heterogeneity of Pf 
transmission intensity can influence the risk of malaria in children but when adjustments were 
made for differences in climatic conditions and differences in bed net use, the association 
between PM and early infant malaria were still significant [30,31]. Therefore PM is an 
independent predictor of risk of early Pf infection after birth. Other authors have shown an 
association between PM and higher risk of severe malaria, anemia and non-malarial febrile 
episodes, as well as lower ability to cope with cognitive tasks during childhood [28,32–35]. 
Although these long-term health outcomes have been described, the underlying 
mechanisms linking PM with increased infant susceptibility to malaria have not been well 
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elucidated. Nevertheless, the findings support the fetal origin of disease concept which purports 
that childhood and adulthood predisposition to disease is conditioned, to some extent, by the 
intrauterine environment. The concept was first described in 1995 by the British epidemiologist 
David Barker after he noticed an association between mortality from coronary heart disease in 
adults and disproportionate fetal growth [36]. In his study of 16,000 adult men and women born 
between 1911 and 1930, Barker demonstrated that death rates from coronary artery disease were 
highest in adults who weighed less than 2,500g at birth, not as a result preterm delivery but 
because of intrauterine growth retardation [37,38].  
DEVELOPMENT OF THE FETAL IMMUNE SYSTEM 
The fetus is not immunologically dormant. Development of the immune system in 
humans begins during the embryonic period and continues throughout gestation.  Beginning at 2 
weeks of gestation, the yolk sac produces primitive hematopoietic precursors that migrate to the 
aorta gonad mesonephros region and to the liver. The fetal liver is the primary site of 
hematopoiesis from 6 weeks of gestation to about 10 weeks when the bone marrow takes over.  
Well-differentiated neutrophils, macrophages, NK cells, dendritic cells, T cells and B cells have 
been detected in fetal tissues by 10–12 weeks of gestation [39]. Many components of the adult 
innate and adaptive immune systems are present during early intrauterine life. 
Ontogeny of the fetal innate immune system 
The intra-uterine environment is relatively sterile as the fetus enjoys the privilege of 
being semi-walled off from the maternal genital tract by fetal membranes and from maternal 
circulation by the placenta. The placenta is fully formed with IVS by week 13 of gestation and 
continues to grow in size throughout pregnancy to attain a weight of about 1 pound at birth [14]. 
Other fetal organs such fetal skin, lung mucosa and gut mucosa serve as second-line physical and 
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chemical barriers against pathogens. These organs produce several anti-microbial peptides in 
amounts that increase with gestational age [40]. Thus, preterm babies are at higher risk of severe 
mucosal diseases such as necrotizing enterocolitis than full term babies and adults.  
The number and functional capacity of fetal innate blood cells also vary with gestational 
age. In a rare study of differential cell counts in blood obtained by cordocentesis from 316 
fetuses of gestational ages ranging from 18 to 40 weeks, Davies and colleagues [41], found that 
average total leukocyte counts increased from approximately 3,000/µL at 18 weeks to 5,000/µL 
at 30 weeks and 12,000/µL at 40 weeks. Average neutrophil counts remained under 1,000/µL 
until 32 weeks and increased exponentially to about 8,000/µL at 40 weeks. White blood cells in 
preterm fetuses also have a limited ability to extravasate into infected tissues because of 
decreased expression of integrins, such as leukocyte functional antigen (LFA-1), another reason 
why preterm newborns are more susceptible to bacterial infections than term newborns [42]. 
Monocytes, but not neutrophils, are important in the control of malaria parasitemia. Monocyte 
numbers and expression of pro-phagocytic markers like CD32, are higher in term compared to 
preterm newborns [41,42]. However, this may not affect Pf parasitemia of preterm and full-term 
newborns because prenatal and congenital malaria rarely occur in the first place.  
Like in adults, the fetal innate immune system is equipped to recognize specific microbial 
molecular signatures called pathogen-associated molecular patterns (PAMPs). Expression of 
many known cell surface and cytosolic pattern recognition receptors (PRRs) has been confirmed 
in the fetus [43–45]. All known human Toll-like receptors (TLR) are expressed in the fetus 
including those that recognize the Pf PAMPs glycosylphosphatidylinositol (TLR 1, 2, 4 and 6) 
and Pf DNA/hemozoin pigments (TLR9) [46]. Downstream TLR signaling molecules such as the 
adaptor protein MyD88 and transcription factor NFĸb have also been detected in fetal 
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membranes and other fetal tissues [45]. With regards to cytokine production, the fetal 
environment tends to be skewed towards an anti-inflammatory state. Upon TLR stimulation, cord 
blood monocytes and antigen-presenting cells (APC) express reduced levels of tumor necrosis 
factor-alpha (TNFα), interferon gamma (IFNγ), interleukin (IL) 12, and IL1β mRNA, but higher 
levels of IL10 mRNA compared to adult monocytes and APC [47]. IL10 production declines to 
adult levels at 1 to 2 years of post-natal life. The anti-inflammatory bias in utero may be 
important in preventing preterm labor and miscarriages. 
Fetal inflammatory response syndrome 
 Even though the intrauterine environment is largely anti-inflammatory, the fetus is 
capable of mounting strong inflammatory responses when exposed to significant amounts of 
aggression. A classic example of prenatal inflammatory response is fetal inflammatory response 
syndrome (FIRS), described by Gomez and coauthors in 1998 [48]. The syndrome is 
characterized by a systemic activation of the fetal innate immune system and systemic release of 
pro-inflammatory cytokines, particularly IL6, but also, IL8, TNFα, and IL1β. The hematologic 
profile [49], leukocyte transcriptomic pattern [50], monocyte phenotypic changes and metabolic 
alterations [51] during FIRS are similar to those observed in systemic inflammatory response 
syndrome (SIRS) of adults. The most common etiologies of FIRS are microbial infections, such 
as group B Streptococcus, that invade the amniotic cavity from the maternal genital tract after 
preterm prelabor rupture of fetal membranes [52]. Increase in levels of pro-inflammatory 
cytokines in cord blood has also been observed in the absence of intra-amniotic infection, 
suggesting that hematogenous agents that invade the placenta can induce FIRS. Cytomegalovirus 
infection has been shown to elicit FIRS in animal models [53]. It is not yet clear if fetal exposure 
to Pf or Pf products elicits FIRS. 
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Ontogeny of the fetal adaptive immune system 
The fetal thymus is formed at about 6 weeks of gestation and is seeded by T cells by 10 
weeks [39]. Unlike mice in which transitional T cells are not released from the thymus until after 
birth, recent thymic immigrants are present in human fetal blood from 12 weeks of gestation. 
Peripheral T-cell subsets in the fetus are polarized towards T regulatory cells (Tregs). About 15–
20% of CD4+ T cells of secondary lymphoid organs in the fetus are CD4+CD25+FoxP3+, 
compared to less than 5% in the newborn and adults [54,55]. Fetal Tregs play a role in exerting 
peripheral tolerance against maternal alloantigens that the fetus may be exposed to as result of 
maternofetal microchimerism [55,56]. The relatively high frequency of Tregs before birth and 
reversal thereafter also point to a layered immune system [57] in which sequential waves of 
peripheral immune cells with different polarization fates are produced at different times during 
development from distinct precursors. T cells produced during early development may therefore 
arise from precursors that are different from adult T-cell precursors, hence explaining the 
variation in the polarization of effector functions of fetal and adult T cells. 
In addition to peripheral tolerance by Tregs, the developing fetus may become tolerant to 
alloantigens in utero through central mechanisms. Sir Peter Brian Medawar found that 8-week 
old mice did not reject grafts from genetically unrelated adult mouse donors if the graft 
recipients were inoculated with live cells from the same unrelated donor before birth [58,59].  
These observations led to the idea that self and non-self recognition is defined in utero and that 
tolerance to foreign antigens can be actively acquired when the immune system is exposed to the 
antigens before birth. The tolerance observed by Medawar was later attributed to thymic deletion 
of T-lymphocyte clones that are reactive to donor antigens [60]. However, recent advances do 
not fully endorse these original conclusions. As explained later in this chapter, some newborns 
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possess T cells that proliferate and release cytokines in response to challenge by antigens derived 
from pathogens their mothers were infected with during pregnancy. Clearly these T cells had 
been sensitized to the antigens in utero and were not clonally deleted or suppressed by Tregs.  
 Like T lymphocytes, B lymphocytes develop early during fetal life. By 8 weeks of 
gestation, pre-B cells expressing cytoplasmic IgM can be detected in the fetal liver [39]. The pre-
B cells become immature B cells expressing surface IgM by 10–12 weeks gestational age. At 12 
weeks, B cells expressing IgM, IgD, CD19 and CD20 are present in peripheral circulation. Over 
90% of circulating B cells in the human fetus express CD5 [61,62], the characteristic phenotypic 
marker of murine B-1 cells. Mouse B-1 cells spontaneously produce poly-reactive, 
predominantly IgM antibodies in a T-independent manner, in contrast to conventional B-2 cells 
that are T-dependent and antigen-specific. Based on the high prevalence of CD5+ B cells in 
utero, it was originally considered that human fetuses were incapable of mounting antigen-
specific B-2 responses. However, recent advances refute this concept because human B cells that 
are functionally identical to mouse B-1 cells do not share the same phenotype as mouse B-1 
cells. That is, human B-1 cells express the phenotype CD20
+
CD27
+
CD43
+
CD70
- 
and comprise 
less than 10% of total umbilical cord blood B cells [63,64]. Thus, conventional B-2 responses 
can be mounted by the human fetuses. The mouse-human discordance in fetal B-1/B-2 cell 
proportions and the absence of T cells in mouse peripheral lymphoid organs until after birth 
(whereas present in human fetal spleens and lymph nodes at 12 weeks of gestation) are two 
examples highlighting disparities between mouse and human fetal immunobiology. Moreover, 
the duration of gestation in humans (about 280 days) is approximately 14 times longer than in 
mice (about 20 days).  Overall, the newborn mouse can be likened immunologically to a human 
fetus at very early stage of prenatal development. 
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Peripheral lymphoid organs in the fetus are populated with B cells by 16–21 weeks of 
gestation [65]. Initially, the B cells are diffusely spread within the lymphoid tissue, but become 
organized around resident dendritic cells to form primary follicles at approximately 17 weeks in 
lymph nodes and 24 weeks in the spleen. However, secondary follicles with germinal centers are 
thought to be absent in the fetus. Germinal centers are specialized immunologic 
microenvironments where immunoglobulin gene recombination leading to class switch from IgM 
to other antibody isotypes, and somatic hypermutations leading to affinity maturation and 
differentiation of high affinity B cells into long-lived plasma cells and memory B cells occur 
[66,67].  Al Barzanji and collaborators, studied spleen sections of 235 stillbirths and found no 
secondary follicles [68]. Splenic germinal centers were observed only in babies who died no less 
than 2 weeks after birth and the frequency of germinal centers increased with post-natal age [69].   
The observed absence of germinal centers in utero may suggest that the fetal immune 
system is not mature enough to make the germinal centers or may simply reflect a relative lack 
of antigenic exposure in utero. Antigenic stimulation is important for germinal center formation 
and direct contact with a very diverse microbial environment after birth procures more antigenic 
exposure than a fetus would acquire in utero through the mother. In addition, maternal infections 
were unlikely etiologies of stillbirth in the study by Al Barzanji and colleagues [68] which was 
conducted in the United Kingdom where the burden of infections during pregnancy is low. 
Furthermore, some evidence that germinal centers may be produced in utero if the fetus had the 
right amount of antigenic exposure was provided by Wittenbrink and co-workers [70]. Peripheral 
blood samples of preterm babies born at 25–29 weeks were collected at different time points 
after birth. Premature contact with extrauterine environmental antigens was found to stimulate 
class-switch recombination and somatic hypermutations in immunoglobulin genes. However, 
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mutation frequencies were significantly low in newborns compared to adults [71] and preterm 
babies – despite exposure to environmental antigens – had low numbers of mutations until they 
reached a post-conception age corresponding to full term pregnancy [72]. Therefore, the 
generation of germinal centers in utero appears to be both antigen exposure-dependent and 
maturity-dependent.  
Class-switch recombination occurs in utero, but the ability of the switched 
immunoglobulins to respond to a wide variety of antigens is shaped by the diversity of the 
immunoglobulin repertoire. Repertoire diversity is achieved through recombination in the VDJ 
segments of immunoglobulin variable region genes and N-nucleotide additions between 
segments. Rechavi and colleagues [71] reported an increase in the diversity of B cell repertoire 
with gestational age after conducting a cross-sectional study of  four neonates born at 12, 13, 22 
and 26 weeks. Other investigators have reported a higher occurrence of features of repertoire 
immaturity such as short complementarity determining regions (CDR) and over-representation of 
certain VDJ segments, as well as a slower rate of diversification of IgG repertoire after birth in 
premature than term babies [72]. The enzyme required for N-nucleotide addition is also 
expressed only late during fetal life, thereby further restricting the B cell repertoire during early 
gestation. Gestational age-related restrictions in T cell receptor repertoire have also been 
reported [71,73].  
Even though there are limitations in the repertoire diversity and affinity maturation of 
antibodies produced in utero, the fetus benefits from maternal antibodies that are transferred 
across the placenta. Passive transfer of IgG from maternal to fetal circulation increases with 
gestational age as the placenta matures. The rate of increase in total IgG in fetal plasma is slow 
before 22 weeks, moderate between 22 and 26 weeks, and very rapid after 26 weeks [39]. 
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Maternal IgG is transported across the placenta with the help of Fc-neonatal receptors [26,74,75]. 
IgG in the IVS of the placenta are trapped into pinocytotic vesicles at the maternal surface of 
syncytiotrophoblastic cells. While other contents of the pinocytotic vesicles may be digested, the 
IgG is not because it binds to FcRn. At low pH on the fetal side of the syncytiotrophoblast, the 
vesicles fuse with the cell membrane and IgG is released from the FcRn into the fetal circulation. 
The efficiency of IgG transplacental transport also depends on the subclass of IgG, with IgG1 
being the most efficiently transported [76]. FcRn do not bind IgM, therefore maternal IgM is not 
transferred to the fetus. Hence, IgM detected in cord blood is made by the fetus.  This fact has 
been explored in investigations of fetal antibody responses to prenatal antigenic exposure, 
including exposure to Pf. 
FETAL IMMUNE RESPONSES TO PLASMODIUM FALCIPARUM: TOLERANCE VERSUS 
SENSITIZATION  
As described above, the fetal immune system is not inert but there are differences in the 
quality, quantity and breadth of immune responses the fetus can make compared to adults and the 
quality of the response also changes with increasing gestational age. Yet, these differences are 
not necessarily, or solely, reflective of an immature fetal immune system; but also result from a 
relative lack of antigenic exposure in utero particularly during normal gestation. For example, 
the fetus is inclined towards maintaining an anti-inflammatory environment, but severe bacterial 
and viral infections can induce FIRS [48,52,53].  
In addition, fetal T lymphocytes are polarized towards regulatory T cell responses, but 
several studies have demonstrated prenatal T-effector cell sensitization and non-regulatory T cell 
responses in some neonates exposed to pathogens in utero. Cord blood mononuclear cells 
(CBMC) from Brazilian newborns of mothers with Chagas disease show greater proliferative 
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response to T. cruzi-derived antigens compared to CBMC from newborns of healthy mothers 
[77].  In other studies, CD4 T cells of neonates exposed to hepatitis C virus in utero produced 
more IFNγ than CD4 T cells of control neonates [78] and higher frequencies of IFNγ-expressing 
and IL4-expressing CD4+ T cells were found in newborns of Ascaris lumbricoides infected 
mothers than in newborns of uninfected mothers [79]. In a region experiencing an influenza 
outbreak, T-cell proliferation in response to influenza hemagglutinin was observed in 19% of 
newborns [80]. Likewise, in a highly tuberculosis-endemic area of Kenya, purified protein 
derivative-induced cytokine release from cord blood CD4 T cells was detected in 30% of 
newborns [81]. Finally, filarial antigen-driven T effector responses were demonstrated in about 
50% of newborns whose mothers were infected with Wuchereria bancrofti during pregnancy 
[82]. Thus, the fetus can develop antigen-specific T-cell responses prior to birth. 
In many areas of sub-Saharan Africa where the burden of placenta-trophic infections such 
as Pf malaria is high, fetuses can be significantly exposed to Pf antigens in utero.  The question 
then is whether Pf-exposed fetuses develop tolerance or sensitization to Pf antigens. There are 
data in support of tolerance on one hand and data depicting sensitization on the other hand. The 
data on tolerance demonstrate Pf-induced expansion of fetal Tregs and Treg-mediated 
suppression of sensitized T cells. For instance, the frequency of Tregs was found to be higher in 
newborns from areas of high malaria transmission compared to North American newborns [83] 
and in newborns of PM-positive mothers compared to newborns of PM-negative mothers [84]. 
Furthermore, in vitro culture of cord blood T cells with malarial antigens resulted in the 
expansion of both malaria-specific and polyclonal CD4+CD25hiFoxP3+ T cells [85]. Lastly, 
depletion of Tregs from CBMC of newborns resulted in a decrease in antigen-driven IL10 
production, increase in antigen-driven IFNγ production, and increase in MHC class I and II 
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expression on monocytes [83,84].  Thus, a Treg-driven anti-inflammatory fetal response to 
malarial antigens has been reported. 
On the other hand, strong Pf antigen-driven CD4 T-helper responses without signs of 
Treg suppression have been detected in a considerable proportion of newborns from some 
studies sites across Africa. Investigators have reported increased T cell proliferation and release 
of IFNγ, IL2, IL13, IL4 and/or IL5 in response to Pf antigen stimulation of CBMC from 25–60% 
of Kenyan and Cameroonian newborns. The T cell responses were not induced by nonspecific 
activation, as another study demonstrated responses that were finely specific to defined epitopes 
on alleles of the Pf MSP133 protein [86]. In addition, Pf-specific antibody responses have been 
detected in newborns indicating that fetal B cells were sensitized to Pf in utero. Total IgM in 
cord plasma is higher in newborns born to PM-positive compared to PM-negative mothers [87]. 
Several other studies have detected IgM that binds specific Pf antigens (or Pf whole parasite 
extract), in the cord plasma 2–25% of term African newborns [88–95]. IgM is not passively 
acquired from the mother implying that B cells of the newborn IgM responders encountered Pf 
antigens in utero and differentiated into IgM-secreting plasma cells.  
Some studies have demonstrated in utero tolerance and sensitization in the same 
population of neonates exposed to Pf in utero. In a group of 366 newborns of PM-positive 
mothers from coastal Kenya, 67% had predominantly Pf-induced T cell responses characterized 
by Pf antigen-driven T cell proliferation and IFNγ, IL-2, IL-13, and/or IL-5 production while 
23% had reduced T cell proliferation, reduced IFNγ, IL-2, IL-13, and/or IL-5 production, 
increased IL10 production and high expression of CD4+CD25+FoxP3 Treg phenotype [96]. 
Post-natal follow-up of the newborns revealed that risk of infant malaria is associated to whether 
the infant was sensitized or tolerized to Pf in utero. Compared to the sensitized group, the 
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tolerized group experienced delayed acquisition of functional anti-malarial antibodies and an 
almost two-fold increase in risk of malaria infection during the first three years life [96,97]. 
The reason why lymphocytes are tolerized to Pf in some exposed fetuses while in other 
exposed fetuses the lymphocytes are Pf-sensitized and appear to overcome Treg suppression, is 
not known. The direction the fetal adaptive immune response takes in response to Pf exposure 
could be related to several factors including: timing of Pf exposure during gestation (second 
trimester versus third trimester); the number of times exposed; the duration of each Pf exposure; 
the intensity of Pf exposure (amount of antigen to which the fetus is exposed at a given time); the 
type of exposure (antigen-only versus antigens and PAMPs); and the breadth of Pf antigens to 
which the fetus is exposed. Other non-malarial factors such as co-exposure to other pathogens 
and co-morbidities such as fetal undernutrition and intra-uterine growth retardation may also 
contribute in shaping prenatal responses to Pf antigens.  
Direct assessment of fetal exposure to Pf is difficult because fetal samples are not 
accessible during the course of pregnancy. Nonetheless, evaluation of serially collected maternal 
samples over the course of pregnancy along with placental and cord blood samples collected at 
delivery can provide indirect estimates on the timing, frequency, chronicity and intensity of fetal 
exposure to Pf.  
FIRST YEAR OF LIFE ANTIBODY RESPONSES TO PLASMODIUM FALCIPARUM 
For infectious agents that are not transplacentally transmitted such as enteric pathogens, 
infections during the first year of life constitute primary encounters of the infant with the 
corresponding antigens. The infant will therefore be expected to mount primary immune 
response to such antigens during the 
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 first post-natal exposure. In the case of malarial antigens, primary exposure can occur in 
utero in endemic areas and post-natal infections may constitute secondary exposures. It is not 
known if prenatal exposure to Pf will induce recall antibody responses in the infant at first post-
natal infection. 
Circulating antibodies in infant plasma are comprised of maternal antibodies that were 
translocated across the placenta via FcRn and antibodies produced by the infant in response to 
environmental antigen exposure. The passively acquired maternal IgG decline over time in infant 
plasma and are replaced by actively acquired antibodies. Maternal IgG are believed to wane 
completely by 6 months of life but there is not much evidence supporting the assumption 
particularly in the case of Pf IgG. In addition, the relevance of maternal Pf IgG in protecting the 
infant from malaria is not well established. Some studies have reported protection from infection 
[89,98] while others have reported no association with protection [99–102] or an increased risk 
of Pf in infants who acquired high levels of maternal Pf IgG [100,103,104]. The question if 
maternal IgG are surrogates of protection from Pf during infancy or markers of infection still 
needs to be addressed in studies of well characterized Pf-resistant and Pf-susceptible infants. 
CONCLUSION AND SCOPE OF DISSERTATION  
In summary, infection with the malaria parasite during pregnancy can result in fetal 
exposure to Pf antigens. The fetal immune system is biased against inflammation and towards 
immune tolerance but Pf exposure in utero can sensitize fetal T and B lymphocytes.  
Important knowledge gaps still exist and need to be systematically addressed. More 
studies on prenatal lymphocyte responses to Pf have focused only on T cells, even though 
immunity to malaria is primarily mediated through antibody responses. Also, the majority of 
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studies on T and B cells were done using umbilical cord blood samples only from full-term 
newborns. The characteristics of Pf-specific fetal adaptive responses at different times during 
gestation in relation to maternal Pf infection have not been investigated. In addition, it is not 
known if long-lived plasma cells or memory B cells are generated in utero in response to Pf 
sensitization and if these impact post-natal immune responses to Pf. Prenatal exposure to Pf may 
modify the risk of malaria during early childhood but specific exposure-related factors 
responsible for increased post-natal malaria risk are not well-known 
Therefore, the main goals of the current study were to: 
1. Investigate the timing of fetal antibody responses to Pf antigens to determine if gestational 
age influences the prevalence, isotype, amount, and breadth of fetal antibody responses to Pf 
antigens. 
2. Investigate fetal origins of increased susceptibility to malaria by specifically determining if 
placental parasite density predicts the time to first Pf infection and total number of Pf 
infections experienced during the first year of life. 
3. Determine the influence of prenatal exposure to malaria parasites on the antibody response to 
merozoite antigens during the first post-natal falciparum infection.  
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ABSTRACT 
Plasmodium falciparum (Pf)-specific T- and B-cell responses may be present at birth; however, 
when during fetal development they are produced is unknown. Accordingly, cord blood samples 
from 232 preterm (20-37 weeks of gestation) and 450 full-term (≥37 weeks) babies were 
screened for IgM to MSP1, MSP2, AMA1, EBA175 and RESA. Overall, 25% of the 682 
newborns were positive for IgM to ≥1 Pf antigens with the earliest response occurring at 22 
weeks. Interestingly, the odds of detecting Pf IgM in cord plasma decreased with gestational age 
(adjusted OR [95% CI] at 20–31 weeks = 2.55 [1.14–5.85] and 32–36 weeks = 1.97 [0.92–
4.29]); however, preterm and term newborns had similar levels of Pf IgM and recognized a 
comparable breadth of antigens. Cord blood Pf IgM was associated with placental malaria 
(adjusted OR [95% CI] = 2.37 [1.25–5.54]). To determine if in utero exposure occurred via 
transplacental transfer of Pf-IgG immune complexes (IC), IC containing MSP1 and MSP2 were 
measured in cord blood. The proportion of cord samples with Pf IC increased with gestational 
age but was not associated with Pf IgM, suggesting that fetal B cells early in gestation had not 
been primed by IC. Finally, when cord mononuclear cells from 64 term newborns were cultured 
in vitro, only 11% (11/64) of supernatants had Pf IgM; whereas, 95% (61/64) contained secreted 
Pf IgG. These data suggest fetal B cells are capable of making Pf-specific IgM from early in the 
second trimester and undergo isotype switching to IgG towards term.  
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INTRODUCTION  
In malaria-endemic regions, the fetus may be exposed to Plasmodium falciparum (Pf) 
antigens (Ags) that cross the placenta. Pf-infected erythrocytes (iE), DNA and/or soluble parasite 
proteins have been detected in umbilical cord blood samples of <1% to 55% of newborns in sub-
Saharan Africa [1,2]. The risk of congenital parasitemia increases with high density of iE in the 
placental intervillous space [3] and placental pathology [4,5]. The fetus can also be exposed to Pf 
Ags in the form of immune complexes (IC) [6,7] that are transferred across the placenta via Fc-
neonatal receptors (FcRn) [8]. Both IgG1 and IgG3, the main IgG subclasses produced against Pf 
Ags (9, 10), are efficiently transported by FcRn [11–13]. Since the IVS is formed by the end of 
the first trimester [14,15] and FcRn have been detected in human placentas as early as 8–12 wks 
of gestation [16], fetuses could be exposed to Pf Ags throughout the second and third trimesters. 
At delivery, newborn lymphocytes exposed in utero to Pf can respond to Pf Ags. For 
example, cord blood mononuclear cells (CBMC) from 25-60% of Kenyan and Cameroonian 
newborns secreted IFNγ, IL2, IL13, IL4 and/or IL5 in response to stimulation with Pf Ags [17–
22]. Not surprisingly, cytokine profiles were altered in cord plasma of Tanzanian neonates born 
to  mothers with placental malaria (PM)-associated anemia [23]. In malaria-endemic areas, 
newborns have larger spleens compared to newborns in non-endemic areas [24], suggesting 
splenic lymphocyte proliferation takes place in response to Pf in utero. B cell responses also 
occur in utero as Pf-specific IgG and IgM have been detected in supernatants of in vitro CBMC 
cultures (16, 18) and in cord plasma, respectively. Since maternal IgM does not cross the 
placental barrier, Ag-specific IgM in cord plasma is a suitable biomarker for assessing 
development of the fetal B cell response.  Higher total cord plasma IgM levels have been 
reported in babies born to placental malaria-positive (PM+) compared to PM-negative (PM-) 
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mothers [25], and other studies have detected IgM to an extract of iE and to individual Pf Ags in 
cord plasma of 2-25% of African newborns (16, 20, 24–29). Together, data from previous studies 
performed predominantly in term newborns, show that the fetus is not immunologically naïve as 
T and B cell responses can be developed prior to birth. It remains unclear, however, how the 
fetus responds to Pf Ags at different gestational ages (GA).  
Development of the human immune system begins during the embryonic period and 
continues throughout gestation. Hematopoietic precursors are present in the yolk sac and diffuse 
B lymphocytes have been identified in fetal liver, peripheral blood and spleen by 8–12 wks, 12 
wks, and 13-23 wks of gestation, respectively [32]. Primary follicles begin developing in lymph 
nodes and spleen from 17 and 23 wks, respectively [33], but organized germinal centers that are 
important in class-switching and affinity maturation, were not detected in spleens of European 
stillbirths [34,35]. Absence of germinal centers, however, could be due to low antigenic exposure 
in utero in developed countries and does not necessarily imply fetuses cannot make germinal 
centers. Total lymphocyte counts increase steadily from 20 wks through 40 wks [36] and the B 
cell receptor repertoire diversifies throughout gestation [37,38]. Thus, the GA at which the fetus 
is exposed to Ag may influence the resulting antibody (Ab) response. 
In the present study, fetal IgM Abs to five Pf Ags were assessed in 232 preterm (GA 
range, 20–36 wks) and 450 term newborns (≥ 37 wks) in malaria-endemic areas of Cameroon. 
The influence of GA on the percentage of newborns with Pf-specific IgM, the amount of Pf IgM 
Ab present, and the number of Ags recognized (breadth) was investigated. Since maternal IC can 
cross the placenta and potentially stimulate a fetal Ab response, IC containing MSP1 and MSP2 
Ags were also measured in cord blood and their association with Pf IgM was examined. Finally, 
Ab class-switching from Pf-specific IgM to IgG was evaluated using in vitro CBMC cultures. 
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MATERIALS AND METHODS 
Study population and sample selection 
The archival plasma samples and clinical data used were collected between January 1998 
and August 2001 at the Central Hospital Maternity in Yaoundé, Cameroon. Yaoundé is a 
malaria-endemic area with perennial P. falciparum transmission. At the time of the study, 
individuals received an estimated 1 or 2  infective mosquito bites per month [39,40]. Since the 
samples were collected before the implementation of bed nets and intermittent preventive 
treatment for pregnant women in 2004 [41,42], women most likely were infected several times 
with Pf during pregnancy and their fetuses could have been exposed to Pf iE and/or Ags.   
Preterm and term deliveries were defined as births before and after 37 completed weeks 
of gestation, respectively, calculated from the first day of the last menstrual period. All mother-
newborn pairs with complete clinical data, and born ≥20 gestational weeks were used, providing 
a sample size of 682 newborns. Among the 682 babies, there were 40 sets of twins; however, 
cord blood from only one of each twin was used, so the number of samples (682) equals the 
number of deliveries. Cord plasma from 100 American newborns whose mothers had not 
traveled to a malaria-endemic region during pregnancy were obtained from the University of 
Hawaii Biospecimen Repository and used as negative controls. 
For in vitro Ab studies, cord blood samples were also collected between July and 
November 2014 from 64 Cameroonian term newborns. The neaonates were born during peak 
malaria transmission periods in the Nkolbisson (July to October) and Maroua (October to 
November) health districts of Cameroon. Newborns of HIV-positive mothers were excluded. 
About 5 mL of blood was drawn from the umbilical vein after clamps had been placed at the 
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sectioned and placental insertion ends of the cord. Blood was collected into EDTA tubes and 
transported on ice to the laboratory for processing and analysis. 
 Ethical approval for samples collected between 1998 and 2001 was obtained from the 
Ethics Committee of the Ministry of Public Health, Cameroon, and the Institutional Review 
Board of Georgetown University, Washington, D.C. Human subject research exemption for use 
of archival Cameroonian and North American samples was obtained from the Human Studies 
Program of the University of Hawaii (CHS#21752). The 2014 study was approved by the 
University of Hawaii Institutional Review Board (CHS#21691) and the Cameroon National 
Ethics Committee for Human Health Research (No2014/02/416/L/CNERSH/SP). 
Parasitological and hematological studies 
Smears of maternal peripheral and placental IVS blood were prepared, stained with Diff-
Quick (Baxter Scientific, Inc., Deerfield, IL), and examined for Pf iE by two microscopists. The 
mother was PM+ if iE were detected in either the peripheral or placental smear or both. Placental 
parasite density was calculated as the percentage of iE per 2,000 total erythrocytes in the IVS. 
Maternal anemia was defined as having a packed cell volume (PCV) of less than 30%.  
Testing for admixture of maternal and fetal blood 
 Polymorphisms at three mini-satellite loci (D1S80, YNZ22 and ApoB) were examined 
using variable number of tandem repeat (VNTR) PCR assays.  Paired maternal peripheral and 
cord blood samples were evaluated to verify that cord blood was not contaminated with maternal 
blood cells, i.e., to confirm that Pf IgM responses in cord plasma were made by fetal B cells and 
not by maternal B cells. Mother-stillborn pairs, in whom risk of admixture was presumed to be 
higher than in mother-livebirth pairs, were selected for the VNTR experiments. To increase 
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sensitivity of maternal DNA detection, DNA was extracted – using the NucleoSpin Blood 
QuickPure kit, (Macherey-Nagel, Germany) – from cord-blood buffy coat containing a much 
higher concentration of blood cells than whole blood. About 100 µL of buffy coat was pre-
diluted in 100 µL of PBS.  
For D1S80, 5′-GAAACTGGCCTCCAAACACTGCCCGCCG-3’ forward primer and 
5’GTCTTGTTGGAGATGCACGTGCCCCTTGC-3’ reverse primer were used [43]. For 
YNZ22, 5’-AGGGAGAGAAAGGTCGAAGAGT-3’ f-primer and 5’-
GCCCCATGTATCTTGTGCAGTG-3’r-primer were used [44]. Finally, f-primer 5′-
ATGGAAACGGAGAAATTATG-3’ and r-primer 5'-CCTTCTCACTTGGCAAATAC-3’ were 
used for ApoB [45]. Each 50 µL PCR reaction mix was comprised of 25 µL of 2X GoTaq Green 
Master Mix (Promega, Madison, WI), 2 µL each of f-primer (100ng/µL) and r-primer 
(100ng/µL), 4 µL DNA extract and 17 µL of nuclease-free water. The amplification conditions 
for D1S80 [20], were used for both D1S80 and YNZ22 PCR. ApoB PCR was performed as 
previously described [45], with the addition of an initial denaturation step at 94
o
C for 3 min. 
PCR products were electrophoresed on 2% agarose gel at 5V/cm. For each locus, a mother-
newborn pair was informative if the mother possessed two alleles, one of which is not identical 
to the paternal allele in the newborn. For informative sample pairs, detection of both maternal 
alleles in the newborn indicated the presence of maternal DNA contamination in cord blood. 
Malarial and control antigens 
A panel of malarial Ags was used, including recombinant proteins of the FVO and 3D7 
alleles of 42 kDa C-terminal merozoite surface protein-1 (MSP142) expressed in Escherichia coli; 
the FC27 and 3D7 alleles of MSP2 expressed in E. coli; the 3D7 allele of 83 kDa apical 
membrane antigen-1 (AMA1) expressed in yeast cells; the 60 kDa conserved region II of 
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erythrocyte binding antigen-175 (EBA175) expressed in yeast cells, and synthetic peptide of the 
2.5 kDa ring-infected erythrocyte surface antigen (RESA) containing five EENV repeats. Three 
control Ags were used, including a recombinant dengue virus non-structural protein (DENV-
NS1), dengue virus serotype 2 E protein (DENV2-E) and bovine serum albumin (BSA).  
Coupling of antigens to microplex beads 
 Each Ag was covalently coupled to microplex polysterene beads (Bio-Rad, USA) with 
distinct spectral addresses as previously described [46]. To ensure bead surfaces were saturated 
with Ag, the following amounts of Ag were used per million beads: 1 µg (MSP1-FVO), 1 µg 
(MSP1-3D7), 0.2 µg (MSP2-FC27), 0.2 µg (MSP2-3D7), 1 µg (AMA1-3D7), 1 µg (EBA175), 
10 µg (DENV-NS1), 10 µg (DENV2-E) and 1µg (BSA). Coupled beads were stored in the dark 
at 4
o
C at a concentration of 25,000/µL of blocking-storage buffer (PBS pH 7.2, 1% BSA, 0.02% 
Tween 20, and 0.05% sodium azide).  
Measuring Pf IgM in cord plasma 
A bead-based multi-analyte platform assay was used to measure IgM to Pf and control 
Ags in cord plasma of Cameroonian and North American newborns. Plasma samples were 
diluted 1:100 in PBS-1% BSA and 50 µL was added to 50 µL of a mixture of equal numbers 
(3,000 each) of MSP1-FVO, MSP1-3D7, MSP2-FC27, MSP2-3D7, AMA1, EBA175, and 
RESA-coupled beads in filter plate wells (Millipore, Germany). After 1 h of incubation on a 500-
rpm shaker at room temperature (RT) and in the dark, the plates were washed twice with PBS-
0.05% Tween 20 and once with PBS-1% BSA. Next, 100 µL of 2 µg/mL phycoerythrin (PE)-
conjugated donkey anti-human IgM Ab (Jackson ImmunoResearch, USA) was added to each 
well and incubated on the shaker for 1 h. After three washes, 100 µL of PBS-1% BSA was added 
to each well and beads were re-suspended on a shaker for 5 min before analysis in the LiquiChip 
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100 (Luminex Corp., Austin, TX). Amount of Ab was quantified as the median PE fluorescence 
intensity (MFI) of 100 beads per spectral address. Cameroonian cord plasma were considered 
positive for IgM to Pf Ags if the MFI was greater than the mean + 2 standard deviations (SD) of 
American cord plasma for the corresponding Ag. 
To confirm the binding specificity of Pf IgM, 45 Cameroonian cord plasma samples that 
were positive for MSP1-FVO IgM were tested for IgM to non-malarial antigens that the 
newborns were unlikely to have been exposed to in utero, i.e., BSA, DENV-NS1 and DENV2-E.  
Pf antigen-IgG immune complex assays 
IC were measured in 484 maternal peripheral and cord plasma samples, i.e., 242 mother-
newborn pairs, including 143 preterm pairs and 99 term pairs. Cord samples for IC assays were 
randomly selected from newborns whose mother’s peripheral plasma were also available.  
To capture IC containing malarial Ags, polyclonal anti-MSP1 and anti-MSP2 were used. 
Polyclonal MSP1 and MSP2 antisera were generated by immunizing rabbits with GST fusion 
protein containing full length recombinant Pf MSP1 or 2. Abs were further purified by protein G 
column chromatography and the purity was checked by SDS-PAGE. The Abs were coupled to 
beads at a concentration of 10 ng of anti-MSP1 and 10 ng of anti-MSP2 per million beads.  
Coupled beads were incubated for 1 h at RT with a 1:50 dilution of maternal and cord plasma 
samples. Beads were washed as described above, treated for 1 h with 100 µL
 
of 2 µg/mL
 
of PE-
conjugated goat
 
anti-human IgG (Fcγ fragment specific) (Jackson ImmunoResearch, USA) and 
washed again. The beads were
 
then re-suspended in 100µL of PBS-1% BSA and analyzed in the 
Liquichip 100. Plasma from 20 American adults were also tested to establish MSP1 and MSP2 
IC cut-offs (mean + 2SD). 
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CBMC cultures for in vitro IgM and IgG production 
CBMC were isolated from freshly-collected cord blood of 64 term newborns by ficoll 
density gradient centrifugation. Mononuclear cells were harvested, washed three times with 10 
mL of 2% Fetal Bovine Serum (FBS) and resuspended at 2 x 10
6
 cells/mL of RPMI-1640 
supplemented with 10% Serum Replacement-3 (Sigma-Aldrich), 0.2 M L-glutamine, 0.02 M 
HEPES, 100 IU/mL penicillin G, 100 µg/mL streptomycin sulfate and 0.1 M sodium pyruvate. 
Then, 200 µL of CBMC suspension (4 x 10
5
 CBMC)/well was incubated in triplicate wells in 96-
well U-bottom plates (Corning, USA) for 5 days at 37
o
C and 5% CO2. Wells containing culture 
mediun only were also incubated for 5 days for comparison. All supernatants were harvested and 
stored at -80
o
C until analyzed. 
Measurement of Pf IgM and IgG in culture supernatants 
To determine whether Ab-secreting cells in CBMC had isotype-switched in utero, culture 
supernatants were tested for IgM and IgG Abs to Pf Ags.  The multiplex assay used was similar 
to the plasma assay described above, except: 1) Ags were coupled on Magplex magnetic beads 
(Bio-Rad, USA), 2) culture supernatants were used undiluted, 3) PE-conjugated donkey anti-
human IgG (Jackson ImmunoResearch, USA) was used to detect IgG bound to Pf Ags, and 4) 
the MagPix analyzer (Luminex Corp., Austin, TX) was used to quantify MFIs. Cut-off for in 
vitro IgM and IgG was the mean of the media-only + 3SD. 
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Statistics 
Fisher’s exact test was used to compare proportions and the Chi-square test for trend was 
used to identify significant trends in Pf IgM seropositivity rates across GA groups. Paired t test 
was used to compare levels of IgM to Pf Ags with IgM to control Ags measured in the same 
samples. Changes in levels of IgM or IC across GA groups were analyzed using one-way 
Analaysis of Variance (ANOVA) including post-test analyses for GA-related trends. 
Determinants of the presence Pf IgM in cord plasma, specifically IgM to MSP1 or MSP2, were 
assessed using logistic regression models. Exposure-related variables, i.e., PM and presence of 
Pf IC in cord plasma, as well as GA, were included a priori in the model. Maternal anemia was 
also included in the model because anemia was associated with the breadth of Pf IgM in cord 
plasma. Interaction between PM and GA was also examined. 
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RESULTS 
Preterm newborns 
 A total of 232 out of 682 mothers (34%) had preterm deliveries.  Having a preterm baby 
was associated with higher placental parasite density (median percent iE [25
th–75th percentile] 
was 1.7% [0.6–6.1%] for preterm and 1.0% [0.3–3.4%] for term mothers, p = 0.042), suggesting 
that maternal malaria contributed to preterm births. Other maternal factors associated with 
preterm delivery were younger age (mean ± SD for preterm was 25.6±6.7 years, term = 27.4±6.1 
years, p = 0.001); primigravidity (30% of preterm mothers, 22% of term, p = 0.025); and 
maternal anemia (38% of preterm mothers, 20% of term, p<0.001).  
Based on the World Health Organization’s classification of preterm births [47], 16% of 
the 232 preterm newborns were categorized as extremely preterm (<28 complete wks of 
gestation), 25% were very preterm (28–31 wks), and 59% were moderate to late preterm (32–36 
wks). As expected, preterm singleton newborns had lower birthweights (2,089±710g) than term 
newborns (3,284±554g), p<0.001. Only 6% (43/682) were stillborn, but clinical information 
indicated they were not macerated and their placentas were macroscopically intact. 
Confirmation that admixture of fetal and maternal blood had not occurred 
Maternal IgM does not cross the placenta and previous studies have demonstrated that 
maternal blood does not significantly mix with fetal blood during normal vaginal deliveries at 
term [18,20].  However, 16% of premature newborns were stillbirths (38/232) compared to 1.5% 
(7/450) of term neonates (p<0.001). To evaluate if admixture had occurred, DNA was extracted 
from peripheral buffy coat of 37 stillbirths and their mothers and examined for polymorphisms at 
three mini-satellite loci. Of the 37 mother-stillborn pairs that were genotyped, maternal DNA 
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was not detected in 35 cord blood samples (95%) (S1 Fig. gel A and B) and the other two sample 
pairs were inconclusive as the mother and newborn were either homozygous or had the exact 
same heterozygous alleles (S1 Fig., gel C). Because maternal DNA was not detected in any of 
the stillborn infants, maternal:fetal blood admixture did not have a major influence on the study. 
Hence, detection of Pf IgM in cord blood indicated that the IgM was produced by fetal B cells.  
Pf IgM in cord plasma 
As expected, some Cameroonian newborns had IgM to Pf Ags (Fig. 1A), indicating that 
they had been exposed Pf Ags in utero and made IgM. Based on the cut-off of mean + 2 SD of 
100 American newborns, 6.6% of Cameroonian newborns were IgM positive for MSP1-FVO, 
7.5% for MSP1-3D7, 17.8% for MSP2-FC27, 17.4% for MSP2-3D7, 5.7% for AMA1, 7.2% for 
EBA175 and 8.5% for RESA. Overall, 25% (169/682) had IgM to one or more Pf Ags. 
To confirm the IgM responses were Pf Ag-specific, cord plasma from 45 newborns who 
tested positive for IgM to MSP1-FVO were re-screened for IgM to an irrelevant Ag (BSA) and a 
viral pathogen (DENV) that is uncommon in Yaoundé, Cameroon [48] and does not frequently 
cross the placenta [49,50] (Fig. 1B). MFIs were significantly lower for BSA (mean±SD = 
105±189) compared to malarial Ags MSP1 (991±1,262, p <0.0001), MSP2 (1,130±1,811 MFI, p 
= 0.0003) and AMA1 (1,018±1,763 MFI, p = 0.0009). IgM levels for DENV-NS1 (91±157 MFI, 
p = 0.013) and DENV2-E (81±103 MFI, p = 0.012) were also lower than MSP1 IgM. These data 
show the IgM response to malarial Ags was antigen-specific and not due to cross-reactivity.  
Timing of Fetal Pf IgM response to Pf antigens 
 Stratification of the IgM response by GA showed a strong trend for a decrease in the 
proportion of IgM-positive newborns with increasing GA, i.e., the highest percentage of Pf IgM+ 
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were in the extremely preterm, followed by very preterm, moderate to late preterm, and term 
newborns (Fig. 2A). This trend was particularly significant for IgM to MSP1 (p = 0.008), MSP2 
(p = 0.0006) and RESA (p = 0.002). The proportion of newborns who were positive for IgM to 
≥1 Pf Ags also decreased steadily from 37% at 20–27 wks, to 33% at 28–31 wks, and 31% at 
32–36 wks, followed by a sharp decline to 21% at ≥37 wks. These results demonstrate that B-cell 
sensitization occurred early in gestation and was not impaired in premature fetuses. 
The level of IgM to Pf Ags in Ab-positive newborns was comparable in preterm and term 
newborns (Fig. 2B). Average IgM levels did not differ significantly among the different GA 
groups (one-way ANOVA: MSP1-FVO (p = 0.960), MSP2-FC27 (p = 0.887), AMA1 (p = 
0.826), EBA175 (p = 0.566) and RESA (p = 0.145).  Therefore, sensitized B cells of preterm and 
term fetuses produce similar levels of Pf IgM. 
Since the overall B cell repertoire increases during fetal development, the number of Pf 
Ags recognized with increasing GA was evaluated (Fig. 3). Among the 169 newborns who were 
IgM-positive for ≥1 Pf Ag, 15% of preterm (11/75) and 14% (3/94) of term newborns made IgM 
to all 5 Pf Ags, i.e., MSP1 (FVO or 3D7), MSP2 (FC27 or 3D7), AMA1, EBA175 and RESA.  
In addition, 21.4% (3/14) of extremely preterm newborns had IgM to all 5 Pf Ag compared to 
14% of term newborns, but the difference was not significant (p = 0.433). These findings suggest 
that the repertoire of B cell clones to Pf Ags was not restricted when the fetuses were exposed to 
Pf.  A significant association was found between maternal anemia and presence of cord IgM to 
3–5 Ags (56% were anemic) versus 1–2 Ags (29%) (p = 0.001) (S1 Table). 
In summary, these data demonstrate that preterm fetuses can produce similar amount of 
IgM to as many Pf Ags as term fetuses. Interestingly, the proportion of IgM responders for each 
and at least one Pf Ag significantly decreased with GA.  
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Timing of fetal exposure to Pf antigen-IgG immune complexes 
 Peripheral plasma samples from 242 mothers who had preterm (n = 143) and term (n = 
99) deliveries were tested for IC containing MSP1 and MSP2. Overall, 77/242 mothers (32%) 
had IC containing MSP1or MSP2.  Since these mothers had the potential of transferring IC to 
their fetuses, corresponding cord blood samples were tested for IC (Fig. 4). Results showed that 
IC were uncommon in cord plasma prior to 32 weeks of gestation, but rose quickly, such that 
65% and 55% of term newborns had IC containing MSP1 and MSP2, respectively (Fig. 4A).  
Likewise, the amount of IC in cord plasma rapidly increased after 32 weeks of gestation (Fig. 
4B). No significant differences in IC levels were found between PM+ and PM- mothers (data not 
shown). Altogether, the GA-related pattern observed for cord IC (Fig. 4) was essentially the 
reverse of that found for cord IgM Ab (Fig. 2).  
Factors associated with presence of fetal Pf IgM  
 To determine which factors were associated with presence of IgM to Pf Ags in cord 
blood, a logistics model was employed including GA, PM status, presence of IC, and maternal 
anemia (which was associated with breadth of the IgM response) (Table 1). In the adjusted 
model, odds of being Pf IgM positive were significant in neonates born very prematurely 
(adjusted OR [95% CI]: 20-31 weeks; 2.55 [1.14-5.85]) and born to PM+ mothers (2.37 [1.25–
4.54]). When an interaction between GA and PM status was evaluated, neonates born to PM+ 
mothers with GA of 20-31 weeks (very premature) had an adjusted risk of 7.87 [2.1-32.2] and 
those with GA of 32-26 weeks had an adjusted risk of 3.46 [1.02-12.5].  Neither IC nor maternal 
anemia were associated with Pf IgM.  
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CBMC of term newborns produce more IgG than IgM  
When CBMC from 64 Cameroonian term newborns were cultured for 5 days and 
supernatants were tested for both Pf IgM and IgG, supernatants from only 11% contained IgM 
≥1 Pf Ag; whereas 95% contained Pf IgG (Table 2). The in vitro IgM levels correlated with the 
plasma IgM levels (MSP1-FVO r = 0.712, p<0.001; MSP2-FC27 r = 0.890, p<0.001; AMA1 
Pearson r = 0.395, p = 0.002; and EBA175 r = 0.880; p<0.001) supporting the conclusion that 
IgM in cord plasma was produced by B cells of fetal origin. No significant difference in the 
proportion of in vitro cultures containing Pf IgM or IgG was found between neonates of PM+ 
and PM- mothers. The finding of Pf IgG responses in newborns of PM-negative mothers 
confirms that prenatal Pf exposure does not occur exclusively close to term delivery but also 
earlier in gestation.  
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DISCUSSION 
The human fetus develops in an intra-uterine environment with relatively little exposure 
to foreign Ags. Therefore, little is known about the timing and nature of acquired immune 
responses during fetal development. Based on mid-20
th
 century observations that fetal mice 
inoculated with cells from unrelated mouse strains were less likely to reject grafts from the donor 
strains after birth [51,52], it was originally thought that fetuses recognize all foreign Ags as ‘self’ 
and became tolerant to them. However, it is clear today that the fetal immune system can 
recognize and respond to pathogens. Pattern recognition receptors for pathogen-associated 
molecular patterns have been identified on various fetal cells [53–55] and the fetal inflammatory 
response syndrome has been describe following microbial invasion of the amniotic cavity [56]. 
In addition, Ag-specific T and B cell responses have been detected in term newborns exposed in 
utero to Pf [17,19,20,22,26,29–31,57]; to other pathogens including rubella virus, hepatitis B 
virus, Toxoplasma gondii, and Trypanosoma cruzi [58–60]; and to inhalant allergens [61,62] . 
However, data on when the fetus can respond to Ags and produces an adaptive response during 
development has been difficult to determine. 
Malaria during pregnancy presents a unique opportunity to study the timing of fetal 
immune responses , since: i) women in high transmission areas test positive for Pf in peripheral 
blood smears an average of 4–5 times during the second and third trimester [63], ii) Pf-infected 
erythrocytes sequester in the intervillous space leading to placental pathology and sometimes 
congenital infection [3,64]; iii) p sequestration of Pf in at the maternal:fetal border can occur 
from 8–12 wks to term [14,15]; iv) mathematical modeling studies calculate that primigravid 
women can harbor chronic placental infections throughout pregnancy [65]; and v) Pf Ags can be 
transported across the placenta as immune complexes [6]. Although not every infective mosquito 
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bite results in PM and transplacental Pf Ag transfer, it is highly probable that many fetuses in 
endemic regions are exposed to Pf Ags from the end of the first trimester through term.  The 
present study is the first comprehensive investigation of fetal Ab responses to Pf Ags in a large 
sample size of neonates (n = 682) born with GAs ranging from 20–44 wks, 34% of whom were 
preterm (<37 wks, n = 232).  
Having Pf IgM in cord plasma was strongly associated with PM (Table 1). Overall, 25% 
(169/682) of Cameroonian newborns, including a 22-wk preterm newborn, were positive for IgM 
to Pf Ags, but not to Ags such as BSA and DENV proteins that they were unlikely to be exposed 
to in utero (Fig. 1A, B, C). Since the Ab response was Ag-specific, the IgM Abs had to be 
produced by conventional B-2 cells and not by B-1 cells that produce ‘innate’ polyreactive IgM.  
Although ~90% of human cord blood B cells express the mouse B-1cell marker CD5 [66,67], 
Griffin et al., [68–70] showed that human B-1 cells are CD20+CD27+CD43+CD70- and only 
comprise about 6% of cord blood B cells. Thus, the potential for B-2 cell responses to Pf 
develops early in humans. 
The ability of the acquired immune system to specifically respond to Ags depends, in 
part, on the diversity of T and B cell receptors. Rechavi et al., [38] reported an increase in fetal 
BCR and TCR repertoire diversity with increasing GA. Thus, one might expect preterm 
newborns to make IgM to fewer Pf Ags than term newborns. Interestingly, the preterm newborns 
in this study made similar amounts of IgM and recognized as many, if not more, Pf Ags than 
term newborns (Fig. 2B and 3). The actual breadth of Pf IgM in premature and term fetuses may 
have been underestimated, given that only 5 out of >700 P. falciparum proteins made by blood-
stage parasites [71]) were used to detect Pf IgM in cord blood. Xi et al. [29] reported that cord 
plasma with high levels of IgM to Pf-infected erythrocytes detected >30 Pf protein bands on 
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Western blots. Thus, it is likely preterm and term newborns made IgM to additional Pf Ags. GA-
related restriction in BCR repertoire diversity does not appear to be the limiting factor in 
determining the breadth of the fetal Pf IgM response. 
Maternal anemia was associated with increased breadth of Pf IgM independently of GA. 
Maternal anemia has previously been linked with higher placental weight to birth weight ratios 
[72,73], meaning that the placentas of anemic compared to non-anemic women, have a large 
surface area. An increase in surface area could translate into an increase in the number of FcRn 
for IC transport resulting in an increase in transcytosis of diverse IC. Therefore, B cells in fetuses 
of anemic women may be exposed to more Pf Ags. 
Pf IgM was detected in cord plasma from 22 weeks of gestation through term, 
demonstrating that in utero exposure to Pf occurring from this early age can elicit a B-cell 
response. However, 22 wks may not be the earliest time point because only one newborn in this 
study was younger (20 wks) and babies born before 20 wks were excluded from the study. 
Because, Pf iE begin sequestrating in the intervillous space from ~12 wks and fetal spleens are 
seeded with B cells over the next 2 months, it is plausible that Pf IgM would be produced by 
some fetuses aged 14–20 wks. 
The proportion of newborns with IgM to Pf Ags decreased with GA (Fig. 3A). After 
adjusting for PM and anemia, early gestation (specifically 20–31 wks) and maternal PM were 
associated with higher odds of having Pf IgM (Table 1). This implies that for a given equivalent 
exposure to Pf, fetal B cells at term are less likely to make Pf IgM than B cells preterm. In vitro 
experiments showed that B cells in term Cameroonian newborns had class-switched from Pf IgM 
to IgG (Table 2). This finding supports previous reports of class-switch and somatic 
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recombination occurring in utero [20,74] and suggests that GCs may be formed in fetuses 
exposed to Pf Ags. It remains to be elucidated if IgG-secreting cells in term newborns are short-
lived or long-lived plasma cells and if Pf-memory B cells are generated in utero.  
  The presence of Pf IC in fetal circulation increased with GA (Fig. 4), with a rapid 
increase during the third trimester. This increase corresponds to the period of rapid placental 
growth and an increase in surface area for transport of nutrients, Ab and other growth factors. 
Also IC transfer to the fetus may be influenced by the size of maternal IC. Since preterm mothers 
had higher parasite density, their IC most likely form under conditions of relative Ag excess. 
Such ICs are small, do not fix complement, and are not easily deposited on trophoblasts for 
transplacental transfer to the fetus. Greater Pf IC deposition occurs in placentas with relatively 
low parasite densities [75].  In the literature,  the relevance of ICs in eliciting immune responses 
in the human and animal hosts is contentiously debated, as ICs can enhance Ag processing and 
T-cell stimulation or suppress responses by masking Ags and blocking T-cell/B-cell interactions 
or exert no effect at all [76]. Since Pf IgM occurred early and transfer of IC later in gestation, Pf 
IC may play a small role in that initial in utero priming if naïve B cells.    
In conclusion, we propose a model for the timing of fetal exposure and Ab responses to 
Pf (Fig. 5). The fetus may be exposed more than once to Pf Ags, from early in the second 
trimester through term. In response to Pf Ags, both preterm (including extremely preterm) and 
term fetuses are capable of producing Abs that specifically recognize Pf Ags; however, the Ab 
response during the second trimester are predominantly IgM while term fetuses predominantly 
make IgG to Pf Ags.   
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Figure 1. IgM to Pf antigens in Cameroonian and USA cord plasma samples. (A) The level of Pf 
IgM Abs in 682 Cameroonian (Cam) and 100 American cord plasma samples. The horizontal 
lines represent the cut-off for IgM positivity (mean + 2 standard deviations of the USA controls). 
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The vertical dotted box within Cam MSP1-FVO shows the 45 samples used in Fig. 1B and C. 
The binding specificity of 45 cord samples positive for IgM to MSP1 were tested on (B) BSA 
and (C) two Dengue virus proteins (DENV-NS1 and DENV-2 E).  Mean MFI for a dengue IgM 
positive control was 4,003 MFI for DENV-NS1 and 847 MFI for DENV2-E (data not shown).  
Statistical significance was assessed using paired t test. The p values: *p<0.01 and ***p<0.0001.  
MFI = Median Fluorescence Intensity   
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Figure 2. Timing of the prenatal Pf IgM response.  (A) The percent of newborns (n = 652) 
positive for IgM to Pf Ags. The proportion of IgM-positive newborns decreased with gestational 
age, Chi-square test for trend: MSP1 (3D7 or FVO), p = 0.008; MSP2 (3D7 or FC27), p = 
0.0006; AMA1, ns; EBA175, ns; RESA, p = 0.002. (B) Amount of IgM Ab present for newborns 
who were Ab positive for the specified antigen.  Average IgM levels did not differ significantly 
with GA for any of the antigens (ANOVA). 
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Figure 3. Breadth of Pf IgM response in different gestational age groups. The 169 Cameroonian 
newborns who were positive for cord IgM to ≥ 1 Pf Ag were included, i.e., n = 75 preterm [n = 
14 (20-27 weeks), n = 19 (28-31 weeks), n = 42 (32-36 weeks)] and n = 95 term. For each GA 
group, the bars represent the proportion of positive newborns that produced IgM recognizing 1, 
2, 3, 4 and 5 Pf blood-stage Ags.  There were no significant (ns) differences between different 
GA groups.
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Figure 4. Timing of fetal exposure to maternal immune complexes (IC). Peripheral plasma 
samples from 242 mothers were tested for Pf-specific IC and 77/242 had MSP-1 C and 77/242 
had MSP2 IC. Cord plasma from their 77 newborns were assessed for IC transfer. (A) The 
percentage of cord blood samples with IC increased with GA all neonates.  B. Average levels of 
Pf-specific IC in cord plasma.  P values were calculated using one-way ANOVA with post-test 
for linear trend: *p<0.01 and **p<0.001. 
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Table 1. Influence of gestational age and placental malaria on production of Pf IgM to MSP1 and 
MSP2 in utero 
Criterion Subgroup % of n Cord IgM (MSP 1 or 2) 
Crude odds ratio  Adjusted odds ratio 
OR 95% CI  OR 95% CI 
GA, weeks
 a
 20-31
b
  27% 1.76 [0.85-3.62]  2.55 [1.14-5.85] 
 32-36
 
 32% 1.55 [0.77-3.13]  1.97 [0.92-4.29] 
 ≥37  41% Ref.   Ref.  
 
PM
 a
 
 
Yes 
 
40% 
 
1.93 
 
[1.08-3.48] 
  
2.37 
 
[1.25-4.54] 
 No 60% Ref     
 
Cord IC (MSP1 or 2)
 a
 
 
Yes 
 
16% 
 
1.22 
 
[0.55-2.58] 
  
1.48 
 
[0.63-3.35] 
 No 84% Ref   Ref.  
 
Maternal anemia
 a
 
 
Yes 
 
33% 
 
1.80 
 
[0.99-3.26] 
  
1.48 
 
[0.79-2.75] 
 No 67% Ref   Ref.  
 
GA:PM interaction
 c
 
 
20-31: PM-
yes 
 
7% 
 
7.93 
 
[2.21-31.41] 
  
7.87 
 
[2.11-32.31] 
 32-36: PM-
yes 
10% 3.70 [1.14-12.84]  3.46 [1.02-12.45] 
 ≥37: PM-yes 23% 2.06 [0.74- 6.31]  1.92 [0.69-5.94] 
 20-31: PM-no 20% 1.79 [0.61-5.65]  1.85 [0.62-5.97] 
 32-36: PM-no 22% 1.96 [0.70-6.05]  1.88 [0.66-5.92] 
 ≥37 : PM-no 18% Ref   Ref.  
a 
Each variable was adjusted for all other variables (excluding the interaction variable) in the table. 
b
 
Extremely preterm (20-27 wks) and very preterm (28-31wks) newborns were grouped together for 
this analysis. 
c 
Interactions between GA and PM were adjusted for maternal anemia and cord IC.  
Note: OR, odds ratio; CI, confidence interval; Ref., reference subgroup; GA, gestational age; PM, 
placental malaria; IC, immune complex; n = 242 newborns. 
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Table 2. Percent of Cameroonian neonates whose cord blood mononuclear cells produced Pf 
specific IgM and IgG in vitro 
 Cord plasma IgM  In vitro IgM  In vitro IgG 
Antigen PM 
neg. 
n=24 
PM 
pos. 
n=35 
All 
n=64 
 PM 
neg. 
n=24 
PM 
pos. 
n=35 
All 
n=64 
 PM 
neg. 
n=24 
PM 
pos. 
n=35 
All 
n=64 
MSP1 0 6 3  0 3 2  67 80 77 
MSP2 4 14 9  0 3 2  33 49 45 
AMA1 4 17 11  4 3 3  83 80 81 
EBA175 4 9 6  8 3 5  50 51 53 
RESA 0 9 5  8 11 9  50 63 56 
≥1 Pf Ag 8 20 14  12 11 11  92 97 95 
Data are presented as percent of neonates. PM status was not available for 5 mothers. ≥1 Pf Ag = 
had Ab to one or more tested Ag in cord plasma or CBMC supernatant. 
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Figure 5. Model for the timing of fetal exposure and Ab responses to Pf Ags. The proportion of 
fetuses in this study making IgM or IgG to at least one Pf Ag is represented by solid and dotted 
lines. Solid portion of lines represent data from the present study. Dotted portion of lines are 
hypothetical projections. The timing of exposure to Pf Ags is shown in horizontal bars (Gray 
scale: Dark = High, Light = Low).  Infected erythrocytes sequester in the IVS towards the end of 
the first trimester (~12 wks).  The higher  incidence of maternal malaria and higher placental 
parasitemia at 13-20 wks increase the risk of exposure and a  significant proportion of fetuses 
respond by making Pf IgM during the second trimester. As gestation advances, fetal B cells 
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receive secondary Pf exposures and class-switching to IgG occurs. The proportion of fetuses 
with Pf IgM drops rapidly at term while the proportion of Pf IgG responders increases to almost 
95% at 40 weeks. 
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Supplementary table 1. Factors associated with the breadth of Pf IgM in cord plasma 
 
 
Factors 
Number of Pf Ags recognized by Pf IgM 
responders 
 
P  
Value 
 
Adjusted  
P Value
a
 1 or 2 Pf Ags 3–5 Pf Ags  
 
Number of deliveries 
 
123 
 
46 
  
 
Fetal factors 
    
Live births
b
 113 (92%) 42 (91%) 1.000 0.484 
Twin delivery
b
 7 (6%) 0 (0%) 0.192 0.987 
Birth weight in grams
c
 2675±936 2785±825 0.497 0.999 
Placental weight in grams
c
 571 ±155 588 ±147 0.555 0.750 
Preterm delivery
b
 58 (47%) 17 (37%) 0.297 0.277 
 
Maternal factors 
    
Age in years
c
 26.9±6.7 26.2±6.7 0.516 0.500 
Primigravid women
b
 29 (24%) 15 (33%) 0.242 0.228 
Anemia
b
 34 (28%) 23 (50%) 0.003 0.001 
Malaria positive
b
 35 (28%) 17 (37%) 0.351 0.552 
Parasite density in %
d
 0.05 [0.01 – 0.73] 0.10 [0.01 – 0.43] 0.619 0.506 
The analyses include 169 Cameroonian newborns who had IgM to at least one of 5 Pf Ags 
(MSP1-FVO or 3D7, MSP2-FC27 or 3D7, AMA1, EBA175, RESA).  
a
 Multivariate analyses (logistic regression model including all variables in the table). 
bNumber percent (Fisher’s exact test) 
c
Mean±standard deviation (Student t test) 
d
Median [25th – 75th percentile] (Man-Whitney U test) 
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Supplementary figure 1. Genotyping of VNTR loci for detection of maternal blood admixture 
with cord blood. Bands represent peripheral maternal blood (M) and cord blood (C) VNTR 
alleles for mother-stillborn sample pairs (SP). Eight SPs (out of 37 SPs analyzed) are 
represented. Gel A shows D1S80 alleles in SP1through SP7. Maternal DNA was not detected in 
cord blood compartments of SP1, 2, 3, 4 and 5. SP6 and SP7 were not informative at the D1S80 
locus since the mothers were homozygous. Gel B shows YNZ22 alleles for the same SPs. SP1, 2, 
3, 5, 6 and 7 were informative, showing no maternal DNA in cord blood. SP4 was not 
informative at the YNZ22 locus. Overall, analyses of both D1S80 and YNZ22 successfully ruled 
out maternal DNA in cord blood of 35 (out for 37) SPs. Gel C shows one (SP8) of the two SPs 
that were not informative after genotyping of all three VNTR loci (D1S80, YNZ22 and ApoB).
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ABSTRACT 
Background: Placental malaria (PM) may increase susceptibility to Plasmodium falciparum (Pf) 
in early childhood. The role of placental parasitemia at delivery as a predictor of susceptibility 
was evaluated. 
Methods: Seventy-two newborns were classified as PM-negative (PM–), PM-positive with low 
parasitemia (PM+Lo) and PM-positive with high parasitemia (PM+Hi) based on placental 
parasitemia at delivery, and were monitored monthly through the first year of life for malaria.  
Results: Time to first infection was significantly shorter in PM+Lo compared to PM– infants 
(p=0.001, by microscopy; p=0.002, by PCR), but not different between PM– and PM+Hi infants. 
The adjusted hazard ratios (95% confidence interval) for infections detected by microscopy/PCR 
were 2.8 (1.3–6.0)/3.9 (1.8–8.4) for PM+Lo and 1.5 (0.7-3.1)/1.5 (0.7-3.4) for PM+Hi, compared 
to PM– infants. Being PM+Lo at delivery was also associated with fewer maternal infections and 
lower peripheral parasitemia during pregnancy, and lower likelihood of Pf DNA in cord blood. 
Conclusion: Low placental parasitemia is associated with reduced fetal exposure to Pf and 
increased risk of malaria during infancy.  Therefore, malaria control regimens such as 
sulfadoxine-pyremethamine that reduce but do not eliminate placental Pf in areas of moderate 
drug resistance may increase the risk of malaria in infants. 
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INTRODUCTION 
 When pregnant women become infected with Plasmodium falciparum (Pf), parasitized 
erythrocytes adhere to placental villi and accumulate in the intervillous space (IVS), causing a 
condition referred to as placental malaria (PM) [1].  In addition to eliciting adverse pregnancy 
outcomes [2], PM has been identified as an independent risk factor of increased early childhood 
morbidity and mortality.  In general, infants born to PM-positive (PM+) mothers have a shorter 
time to first infection [4,5] and first clinical episode of malaria [6,7], higher incidence of Pf 
infections early in life [3], lower hemoglobin levels [4], and higher risk of dying [5] compared to 
infants of PM-negative (PM–) mothers. However, risk of malaria is not homogeneous among 
infants of PM+ mothers, with some infants having similar risk outcomes as PM- infants [5–9]. 
There is therefore a need to identify specific prenatal factors associated with increased 
susceptibility to malaria in infants of PM+ mothers. 
Factors thought to be important in modifying the susceptibility of infants include 
gravidity and the timing of infection during pregnancy. For example, infants of multigravid 
women in Tanzania had their first microscopic infection 12 weeks earlier than infants of 
primigravid women [6]. Likewise, the adjusted hazard ratio (AHR) for clinical episodes of 
malaria during the first 30 months of life was approximately two times higher in Gabonese 
infants born to multigravidae than primigravidae [10]. When maternal Pf infections occurred 
within 3 months prior to delivery, Ugandan infants were at higher risk of infection than when 
mothers were infected earlier in pregnancy [7]. Since multigravidae tend to have lower 
parasitemias than primigravidae and women infected only late in pregnancy would be infected 
for a short time, it is possible that exposure to low levels of malarial antigens, rather than higher 
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levels, influences early childhood susceptibility; however, no study has directly investigated the 
influence of placental parasite density on the risk of malaria after birth. 
Therefore, the primary objective of the present study was to determine if susceptibility to 
Pf of Cameroonian infants was modified by maternal placental parasitemia at delivery. We 
hypothesized that infants born to mothers with low placental parasitemia (PM+Lo) would have 
shorter times to first Pf infection and experience more infections during the first year of life than 
infants whose mothers had higher parasitemias (PM+Hi) or mothers who were negative for Pf 
(PM–). The secondary objective was to determine if PM+Hi mothers had more infections and 
higher peripheral parasitemia during pregnancy that would, in turn, expose the fetus to higher 
levels of Pf. Fetal cord blood was also examined for evidence of Pf parasites and their products.  
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MATERIALS AND METHODS 
Study Design  
The study was conducted in the rural village of Ngali II, Cameroon, between January 
2001 and May 2005. In this area, P. falciparum transmission is perennial with two rainy (March–
May, September–November) and two dry (December–February, June–August) seasons and has 
an estimate entomological inoculation rate of 257 infective bites/person/year [11]. After 
obtaining written informed consent, 94 mother-newborn pairs were enrolled at delivery and 
infants were subsequently followed throughout the first year of life (Figure 1). Most women 
delivered at the village health center, at which time ~2 mL of peripheral and placental IVS blood, 
5x5x5 cm placental tissue biopsy and ~5 mL cord blood were collected. Placental and cord 
samples were not collected for 14 home deliveries as the placentas were buried before the 
mother-newborn pair came to the health center.  
 Newborns were seen at 8 scheduled visits (Figure 1). In addition, they were monitored at 
home by four village health workers who arranged for sick children to be examined by the 
project physician. At all visits, the infant’s axillary body temperature was measured and finger-
prick blood collected (<0.5 mL <6 months old and 0.5–1 mL >6 months). Infants who were 
blood-smear positive were treated for malaria according to the government policy for treatment 
of childhood malaria.  
 The mothers of 26 infants had been followed monthly from ~14 weeks of pregnancy 
through delivery [11]. Peripheral blood samples were collected at each maternal visit. 
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Parasitological methods 
 During pregnancy, peripheral blood samples were stained with Diff-Quick (Baxter 
Scientific, IL) and examined for Pf-infected erythrocytes (iE) by microscopy. Pf parasitemia 
(iE/µL) was determined by counting the number of iE per 200 WBC and multiplying by the 
individual’s WBC count.  
At delivery, IVS and cord blood samples were examined for Pf by microscopy as 
described above. Placental tissue sections were also examined for Pf parasites and scored as 
presence/absence of Pf. PM+ was defined as the presence of Pf parasites in IVS blood and/or 
placental histosection. The amount of Pf DNA in cord blood was determined using nested 
quantitative PCR (qPCR), consisting of a conventional PCR step followed by qPCR. The assay 
was performed as previously reported [12], with minor modifications: DNA was extracted from 
100 µL of packed red cells premixed with 100 µL of PBS; and GoTaq master mix (Promega, 
WI) and SsoAdvanced SYBR-Green Supermix (Bio-Rad, CA) were used for the PCR and qPCR 
steps, respectively. DNA from in vitro 3D7 parasites was quantified by Nanodrop and serially 
diluted (10 fold) to make standard series. 
During the first year of life, Pf infections were detected by microscopy (as described 
above) and by nested PCR. DNA was extracted using the NucleoSpin kit (MN, Germany) from 
200 µL of blood and the Pf 18S ribosomal RNA gene was amplified as described previously 
[13,14]. Amplicons were electrophoresed through 1.5% agarose gel (5V/cm) and SYBR-stained 
Pf bands were visualized. All Pf DNA-positive samples were evaluated for polymorphisms in 
allelic families of MSP1 block 2-4 (K1, MAD20, and R033) and MSP2 (FC27 and 3D7) [11,14]. 
An infant was considered to have a “new infection” if one or more Pf alleles were detected that 
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had not been present at the preceding visit. Finally, standard strip-based electrophoresis was used 
to assess hemoglobin genotypes HbAA and HbAS using infant blood samples  
Immunological methods 
To assess the degree of protection from placental malaria during pregnancy, the levels of 
IgG and proportion of high avidity IgG antibodies (Abs) to full-length VAR2CSA at mid-
pregnancy (~5months) were measured as previously described [15]. 
To determine the level of passive immunity to Pf acquired by infants in utero, cord blood 
was tested for IgG to the merozoite antigens (Ags) MSP1 and EBA175 by Luminex assay. 
Briefly, 1 µg of each recombinant Ag [16] was coupled to 1 million beads with different spectral 
addresses and then 50 µL of beads (3000 of each Ag) was mixed with 50 µL of diluted plasma 
(1:100 in PBS-1%BSA) and incubated for 1 h on a shaker at room temperature. After two 
washes with PBS-0.05% Tween and one wash with PBS-1%BSA, 100 µL of 1:250 dilution of 
2µg/ml. Phycoerythrin-conjugated goat anti-human IgG (Jackson IR, PA) was added to each 
well and incubated for 1 h. Beads were washed, resuspended in 100 µL of PBS-1%BSA and 
analyzed in the LiquiChip 200 (Luminex, TX). Results are reported as median fluorescence 
intensity (MFI).  
Other laboratory methods 
To further quantify Pf in cord blood, cord samples were tested for Pf-histidine rich 
protein-2 (HRP2) using CELISA kit (Cellabs, Australia). Whole blood was prepared by 
recombining equal volumes of cyropreserved plasma and packed RBC. The assay was conducted 
in duplicate using 100ul of blood per well following the manufacturer’s instructions. Serial 
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dilutions of the positive-control provided in the kit were used to generate standard curves and the 
cut-off for positivity were established as specified by the manufacturer. 
Statistical methods 
The susceptibility of infants to malaria was assessed using data from 72 infants who were 
followed for ≥4 months. The primary baseline predictor was placental parasitemia at delivery: 
PM– (no Pf detected, n = 36), PM+Lo (PM parasitemia <median of all PM+) and PM+Hi (PM 
parasitemia >median). 
Study outcomes were time to first post-natal infection and number of times positive. 
Kaplan-Meier survival curves and log-rank tests were used to compare the median time to first 
infection. Right-censoring was done either at withdrawal from study, death, age 1 year, or end of 
study period, whichever occurred first. Cox regression was used to assess hazard ratios (HR) and 
95% confidence interval (CI). HR was adjusted for covariates that could potentially influence 
susceptibility to infection, including gravidity [6,8]; residence and season at birth [11,17]; 
presence of fetal hemoglobin that influences parasite growth [18]; HbAA versus HbAS [19]; and 
Pf IgG in cord plasma [20,21]. Cord plasma Pf IgG levels were ranked as follows:  rank 1 (>67
th
 
percentile), rank 2 (33
rd
 to 66
th
 percentile) and rank 3 (<33
rd
 percentile). Ranking was performed 
because unit changes in IgG MFI (range 500 to 24,000 MFI) were not expected to have 
significant effect on infant outcome. Finally the average number of Pf infections was compared 
between groups using the Student t test.  
For maternal data and parasite-related factors in cord blood, continuous variables were 
compared across study groups using student t tests and ANOVA post-test for linear trends. 
Categorical variables, such as proportion positive, were compared using Chi-square test.  
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RESULTS 
Time from birth to first infection  
 Half of the mothers were PM+ (n=36) with placental parasitemia ranging from <14 to 
10,521 Pf/µL of IVS blood, with a median parasitemia of 25 iE/µL. Among the PM+ mothers 
only 6% were multigravidae compared to 78% of PM– mothers, p = 0.03. 
 The mean duration of follow up for the 72 infants was 10.2 ± 2.9 months, with 60% 
followed until the last scheduled visit. One infant died at 10.3 months. At least one Pf infection 
was detected in 89% (64/72) of infants during the first year of life, with 45% (29/64) of first 
infections being submicroscopic. Time to first infection detected by microscopy was 5 months 
(95% CI = 4.1–6.2); whereas, first infections detected by PCR occurred significantly earlier at 
3.3 months (2.9–4.1), p = 0.01.  
The median time to first microscopic infection was significantly shorted in infants born to 
PM+ mothers (4.1 months) compared to PM– mothers (6.4 months), p = 0.009 (Figure 2A). 
Further stratification showed that infants in the PM+Lo group experienced a significantly shorter 
time to first microscopic infection compared to the PM– (3.4 versus 6.4 months, respectively, p = 
0.001); however, there was no difference in time to first infection between the PM+Hi and PM– 
groups (5.1 versus 6.4 months, p = 0.2) (Figure 2B). A similar pattern was observed for time to 
first PCR-detected infection (Figure 2C and 2D), i.e., 2.8 months versus 4.0 months for PM+Lo 
and PM– (p=0.002), with no difference between PM+Hi (4.1 months) and PM– (4.0 months). By 
4 months, all babies in the PM+Lo group had experienced ≥1 Pf infections, whereas only 50% of 
infants in the other two groups had become infected. Clinical episodes of malaria (fever plus 
microscopic parasitemia) were diagnosed in 17 infants (24%), but no differences in time to 
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malaria episodes were seen between the groups (data not shown). Since the mean duration of 
infant follow-up was similar across all groups, i.e., 10.2 ± 2.5 (PM–), 10.7 ± 3.1 (PM+Lo) and 
9.6 ± 3.5 (PM+Hi) months (p = 0.494), variations in follow-up duration did not account for the 
PM+-associated differences in infection frequency. Thus, infants in the PM+Lo group had an 
increased susceptibility to malaria compared to infants in the other groups. 
Multivariate assessment of the risk of infection 
 After adjusting for multiple covariates, the HR of infants experiencing a microscopic 
infection was 2.8 (1.3–6.0) for PM+Lo and 1.5 (0.7–3.1) for PM-Hi (Table 1). Adjusted HR of 
infections detected by PCR were 3.9 (1.8–8.4) and 1.5 (0.7–3.4) for PM-Lo and PM+Hi, 
respectively. Thus, infants born to PM+Lo mothers had a 2.8 times and 3.9 times higher risk of 
having microscopic and PCR infections, at different time points during the first year of life 
compared to infants in the PM– group. 
Number of times infants were positive for Pf  
 The 72 infants had a total of 180 microscopic and 253 PCR infections, with 29% (73/253) 
being submicroscopic. The mean number of new microscopic infections was significantly higher 
in PM+Lo (3.4 ± 2.3) compared to PM– infants (2.1 ± 2.0), p = 0.04 (Figure 3A). The PM+Lo 
also experienced more PCR infections (4.7 ± 2.2) than the PM– (3.1 ± 2.1, p = 0.02) and PM+Hi 
(2.7 ± 2.1, p = 0.01) groups (Figure 3B).  Together, time to first infection, number of infections 
and hazard ratios show that having low placental parasitemia at delivery is associated with 
increased susceptibility of infants to malaria.  
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Determining how maternal parasite burden during pregnancy relates to placental Pf 
parasitemia at delivery 
 Overall, PM+Hi mothers had more Pf infections (55% of longitudinal peripheral blood 
samples were slide Pf positive) and higher average parasitemia (9,193 Pf/µL of peripheral blood) 
during the second and third trimesters compared to the PM+Lo (38% and 3,161 Pf/µL) and PM– 
mothers (15% and 1,629 Pf/µL) (Figure 4A and 4B). In contrast, mid-pregnancy levels of IgG to 
VAR2CSA and proportion of high avidity anti-VAR2CSA Ab were lower in PM+Hi (MFI = 
4,055 ± 2,989; percent high avidity Ab = 6.4 ± 2.4%) compared to PM+Lo (5,544 ± 3,323; 8.8 ± 
6.3%) and PM–  (9,279 ±6,060; 21.0 ±12.2%) women (Fig. 4C and 4D).  
Furthermore, the proportion of newborns with Pf-DNA in cord blood increased with 
placental parasitemia (4.8% for PM+Lo versus 38.9% for PM+Hi, p = 0.0006) (Table 2) and a 
case of congenital infection (154 Pf/µL) was identified in the PM+Hi group. Cord HRP2 positive 
rates and amount/ml did not differ significantly between the PM+Lo and PM+Hi groups. 
Collectively, the chance of fetal exposure to Pf and/or malarial Ags was higher in PM+Hi than 
PM+Lo pregnancies. 
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DISCUSSION 
The present study supports the concept that infant susceptibility to malaria can be 
conditioned by prenatal exposure to Pf. The current findings add to the growing body of 
evidence that PM modifies the risk of malaria during infancy and demonstrate for the first time 
that placental parasite density is a major determinant for susceptibility to Pf infections. The 
observation that survival of infants without infection is shorter in PM+Lo group than in all PM+ 
combined, shows that much of the PM-associated infant susceptibility to malaria is paradoxically 
accounted for by low placental parasitemia cases.  
Samples of IVS blood cannot be obtained during pregnancy; however, based on 
longitudinal peripheral blood smear data, PM+Lo mothers seemed to have had a relatively low 
exposure to Pf during pregnancy. The PM+Lo were infected less frequently and experienced 
lower average parasitemia compared to PM+Hi women (Figure 4). Also, ~67% of the PM+Lo 
women were multigravidae compared to only 20% of the PM+Hi women. Mathematical 
modeling of gravidity-dependent immunity to PM suggests that placental iE are more rapidly 
cleared in multigravid than primigravid women [22], which further indicates that the PM+Lo 
women were likely to have had lower placental Pf densities through pregnancy.  
Placental parasite density can affect fetal exposure to Pf.  As shown here and previously 
in studies in Malawi [23], detection of iE in cord blood by microscopy is associated with high 
placental Pf parasitemia. Also, the PM+Hi newborns were more likely to have Pf-DNA presence 
in their cord blood. HRP2 rates were similar between the PM+Hi and PM+Lo groups, possibly 
because HRP2 can circulate weeks after parasites and Pf DNA have been cleared [24]. In 
general, newborns in the PM+Lo group were most likely exposed to lower amounts of Pf Ag and 
Pf pathogen associated molecular patterns (PAMP) compared to the PM+Hi newborns.   
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From an immunological standpoint, the question of how Pf exposure programs the fetus 
for increased or reduced susceptibility to malaria is pertinent. Peripheral tolerance to Pf Ags 
induced by T regulatory cells (Tregs) may be responsible for some of the increase in 
susceptibility. Developmental CD4
+
 T cells are biased towards Tregs which constitute ~15-20% 
of CD4
+
 T cells of fetal lymphoid organs compared to <5% in adults [25,26]. Pf Ag exposure can 
induce the expansion of fetal Tregs which, in turn, suppresses Ag-driven responses by T effector 
cells [27–29]. In contrast, other studies have shown strong Th1 and Th2 effector responses to Pf 
Ags in newborns of PM+ mothers, indicating that in utero Pf  exposure can also result  in T cell 
sensitization [16]. Interestingly, a study in Kenya demonstrated  T cell sensitization to Pf in some 
newborns and T cell tolerance in other newborns of the same cohort [30]. The tolerant newborns 
had ~2-fold increase in risk of malaria during the first three years of life compared to the 
sensitized newborns. The specific factors responsible for the dichotomy in fetal immune 
response to Pf Ag have remained elusive. We propose that the outcome of sensitization or 
tolerance to Pf in utero is influenced by the amount of Pf to which fetuses of PM+ mothers are 
exposed i.e., low exposure inducing tolerance and increased risk of infant malaria and high 
exposure inducing sensitization and reduced risk of malaria.  
Data from animal studies support our proposition. The Ag dose required to stimulate the 
suppressive functions of Tregs in mice is much lower than needed for T effector cells to 
proliferate [31], thus a relatively low Pf Ag concentration in utero would stimulate more Tregs 
than T effectors leading to overall suppression of response to Pf. In addition, mouse transgenic T 
cells with OVA TCR, proliferated very little in the presence of  low OVA doses and Tregs, but 
overcame Treg suppression when the OVA dose was increased ~100 fold [32]. Therefore high 
amounts of Pf may also be required for T effectors to escape Treg suppression in utero.  
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In summary, results from the current and other studies provide evidence that placental 
parasitemia may be a good indicator of the amount of prenatal Pf exposure and can be used to 
predict susceptibility to malaria during infancy. In this study, infants were dichotomized into two 
groups, i.e., below and above the median parasitemia of 25/µL. Clearly, additional studies are 
needed to determine the best cut-off parasitemia if that threshold should be based on Pf densities 
in IVS blood, impression smears, or tissue sections. Nevertheless, infants of women who are Pf-
negative by blood smear of IVS blood, but positive by histology are potentially at high risk of 
malaria during infancy.  
Although the relatively small sample size of infants in the study was a limitation, the 
current study reproduced results from larger studies that reported increased risk of infant malaria 
in infants born to PM+ compared to PM– women. The study was unique in many ways. For 
example, Pf in infants was detected by PCR, in addition to microscopy, which increased 
sensitivity of parasite detection and provided better information on time to first infection. In 
addition, new infections were distinguished from persistent infections by parasite genotyping. 
Previous studies measuring age-specific rates of Pf may have overestimated the frequency of 
new infant infections by scoring all slide-positive infections as new [3,6].  
 In conclusion, the translational implications of the current findings are significant. If low 
placental parasitemia increases the risk of infant malaria, then malaria control interventions 
during pregnancy that do not clear Pf from the placenta, and only reduce the Pf density, could 
increase the risk of malaria in the offspring. This is particularly important because there is are 
reports from parts of Africa of decreasing efficacy of sulfadoxine-pyremethamine in eliminating 
parasites in pregnant women [33,34]. More effective interventions that clear Pf in pregnant 
women are needed. 
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FIGURES AND TABLES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.  Study design. Placental Pf parasitemia was used to classify newborns into 3 groups: 
babies born to PM– (no placental Pf), PM+Lo (<median placental parasitemia), and PM+Hi 
(>median) mothers. Seventy-two infants were prospectively monitored from birth through the 
first year life to assess differences in susceptibility to Pf. Infant follow-up was conducted at 
scheduled time points and in-between if any illness was reported. To estimate the exposure of the 
mother and fetus to Pf during pregnancy, mothers of 26 infants had been followed through 
pregnancy and assessed for Pf infections. Also, cord blood samples were tested for Pf-IE, DNA 
and HRP2. LMP, last menstrual period; IE, infected erythrocytes. 
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Figure 2: Kaplan-Meier curves showing time (in months) that infants survived without 
experiencing Pf infections that were diagnosed by microscopy (A and B) and by PCR (C and D). 
The left panels (A and C) show curves for infants born to PM– mothers (thin solid lines, n=36) 
and PM+ mothers (thick dash-dotted lines, n=36).  In the right panels (B and D), infants born to 
PM+ mothers were further stratified into PM+Lo (thick dotted lines, n=18) and PM+Hi (dashed 
lines, n=18). P-values were obtained by log-rank test and represent significant differences in 
median time to first infection, between the PM+ groups and the PM– reference group. ns, not 
significant. 
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Table 1.  Multivariate Cox regression analysis showing hazard ratios for Pf parasitemia in nfants 
Variable 
 
Subgroup % of 
72 
infants 
Microscopy  PCR 
HR  
(95% CI) 
Adjusted HR  
(95% CI) 
 HR  
(95% CI) 
Adjusted HR  
(95% CI) 
Placental 
Pf 
parasitemia 
at delivery 
High (PM+Hi) 24 1.5 (0.8-2.8) 1.5 (0.7-3.1)  1.1 (0.6-2.1) 1.5 (0.7-3.4) 
Low (PM+Lo) 26 2.6 (1.3-4.8) 2.8 (1.3-6.0)  2.8 (1.5-5.4) 3.9 (1.8-8.4) 
No Pf (PM–) 50 Reference   Reference  
Residence
ф
  Zone B 56 0.7 (0.4-1.2) 0.6 (0.3-1.2)  1.1 (0.6-1.7) 1.0 (0.6-1.9) 
Zone A 44 Reference   Reference  
Gravidity Primigravid 14 1.3 (0.6-3.0) 1.0 (0.4-2.4)  1.0 (0.5-2.3) 0.9 (0.4-2.4) 
Multigravid 69 Reference   Reference  
Season at 
birth 
Heavily rainy 15 0.6 (0.3-1.5) 0.3 (0.1-0.9)  0.7 (0.3-1.6) 0.5 (0.2-1.3) 
Dry 20 0.9 (0.4-1.9) 0.6 (0.2-1.7)  0.8 (0.4-1.7) 1.0 (0.3-2.9) 
Rainy 36 0.7 (0.4-1.3) 0.4 (0.2-1.0)  0.5 (0.3-1.0) 0.6 (0.2-1.2) 
Very dry 29 Reference   Reference  
Hb 
genotype 
HbAS 25 1.0 (0.6-1.9) 1.4 (0.7-2.8)  1.2 (0.7-2.1) 1.3 (0.6-2.5) 
HbAA 75 Reference   Reference  
Cord MSP1 
IgG levels   
Upper tertile 33 0.7 (0.4-1.5) 0.5 (0.2-1.3)  1.3 (0.7-2.4) 1.4 (0.6-3.3) 
Middle tertile 33 0.7 (0.3-1.4) 0.6 (0.3-1.2)  1.0 (0.5-1.9) 1.0 (0.5-2.1) 
Lower tertile 33 Reference   Reference  
¥
Zone A, Central Ngali II village; Zone B, Satellite villages (Okoa, Abondo, Ntouessong) 
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Figure 3. The number of Pf infections infants had during the first year of life. The presence of Pf 
in infant peripheral blood samples was diagnosed by microscopy (A) and by PCR (B). Data is 
represented as mean number of infections plus standard error for each group. Pf genotyping was 
used to distinguish new from persistent infections. Note that the mean duration of infant follow-
up was similar for all groups: PM- (10.2 ± 2.5 months of follow up), PM+Lo (10.7 ± 3.1 months) 
and PM+Hi (9.6 ± 3.5 months), p = 0.494. Abbreviations: PCR, polymerase chain reaction; ns, 
not significant; Pf, Plasmodium falciparum; IVS, intervillous space; PM, placental malaria. 
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Figure 4. Relationship between factors associated with Pf burden during pregnancy and 
placental parasitemia at delivery. Twenty-six mothers (12 PM-, 9 PM+Lo and 5 PM+Hi were 
followed monthly during pregnancy. (A) Shows the percentage of visits they were peripheral 
blood smear-positive for Pf. (B) Average peripheral parasitemia (IE/µL) of all positive visits. (C) 
The levels IgG antibody to full-length VAR2CSA at 5 months of pregnancy. (D) The proportion 
of high avidity Ab to VAR2CSA. Data are shown as mean and standard error. P values represent 
significant difference between the PM+Lo and PM+Hi groups (continuous line) and the trend 
across all three groups (dashed line). ns, not significant. 
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Table 2. Relationship between placental Pf parasitemia and Pf products in cord blood 
 
Analysis of cord blood 
Placental Pf parasitemia at delivery  
P value  No Pf    
(PM–) 
Low  
parasitemia                                                       
PM+Lo) 
High 
parasitemia
(PM+Hi) 
Number of newborns 
tested 
31 21 18 n/a 
iE (microscopy)     
      Percent slide-
positive 
0% 0% 5.9% n/a 
      iE/µL - - 154 n/a 
Pf DNA (qPCR)     
      Percent positive 3.2% 4.8% 38.9% 0.0006 
      Concentration
*
, 
pg/mL 
0.04 0.27 0.84 ± 1.23 n/a 
HRP2 (ELISA)     
      Percent positive 3.2% 19.0% 22.2% ns 
      Concentration
*
, 
ng/mL 
0.20 2.77 ± 2.85 2.85 ± 3.07 ns 
*
Concentration data represented as mean ± SD. No data range is shown where only one newborn 
was positive for the corresponding analyte. P values compare low versus high Pf density groups. 
iE, Pf-infected erythrocytes; n/a, not applicable; ns, not significant 
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ABSTRACT 
Although assumed to be protective, there is no solid evidence that maternal IgG to 
Plasmodium falciparum (Pf) antigens provide protection from malaria. It is also unknown if 
prenatal Pf exposure modifies an infant’s initial antibody (Ab) response to malaria. In a 
Cameroonian birth cohort, infants of mothers with known placental parasitemia were classified 
into three groups based on their susceptibility to Pf infections and first year of life Ab profiles for 
8 Pf antigens were evaluated. Maternal Pf IgG Abs were not associated with resistance to Pf 
infections as no significant differences in antibody levels at birth were found between susceptible 
and resistant infants.  Using longitudinal regression models that incorporated time-varying 
covariates, infants were found to produce Ab to MSP1-42 (3D7 and FVO), MSP2 (FC27) and 
LSA1 following first infection, but not to AMA1 (FVO and 3D7), EBA175, MSP3, CSP or 
RESA. The interaction effect of placental parasitemia at birth and first post-natal Pf infection 
showed a boosting of MSP1 IgG, but not MSP1 IgM, in infants exposed to high amounts of Pf in 
utero and not in those exposed to low antigen amounts. The data show that secondary immune 
responses to MSP1 are generated during primary post-natal infection and suggest that high Pf 
antigen dose in utero sensitizes fetal B cells leading to Pf-memory B cell generation.  
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INTRODUCTION 
Antibodies (Abs) are important mediators of host immunity to Plasmodium falciparum 
(Pf) as demonstrated by the effectiveness of passive administration of purified IgG, from 
malaria-experienced African adults, in treating severe malaria in Thai subjects (1). Ags (Ags) 
expressed by the merozoite stage of the parasite are considered to be key targets of the anti-
malarial IgG (2, 3). In infants, circulating IgG to Pf merozoite Ags are either passively acquired 
maternal Abs or Abs produced by the infant in response to active infections.  However, the 
kinetics of decline of maternal Pf Abs and the natural acquisition of Abs by the infant have not 
been well studied.  
During pregnancy, Pf IgG are transported from maternal circulation to the fetal 
circulation via neonatal Fc-receptors (nFc-R) in placental trophoblasts (4). The nFc-R is an 
active transport system and explains why IgG levels in cord blood correlate with, and are 
sometimes higher than, IgG levels in paired maternal plasma (5, 6). Pf IgG has also been 
detected in breast milk (7, 8) but the IgG acquired through breast-feeding is largely degraded in 
the gastro-intestinal tract (9). Passive transfer of IgG into the fetal circulation is, therefore, not 
sustained after birth resulting in a decline of maternal Pf IgG levels in infant plasma over time. 
The decline is believed to be complete at age 6 months, but there is insufficient evidence in 
support of this assumption. A few studies have systematically examined the decline of maternal 
Pf IgG, but most studies were marred by limitations, such as long follow-up intervals and 
measurement of IgG to a few Pf Ags (10–13).  
The role of maternal Abs in protection of infants from Pf infection is also controversial, 
as hitherto reviewed by Riley et al. (14) and by Dobbs et al.                                                                                                                                                                                                                                                                                                                                                                                                                                                  
15). During the first few months of life, infants are relatively protected from high parasite loads 
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and symptomatic malaria, which has been accredited to protective maternal Abs, but other 
factors could be involved (16–19).  A study in the Southern region of Cameroon found an 
association between the presence of Pf IgG in cord plasma and absence of Pf infections during 
the first 6 months of life (20); however, several other studies either did not find any association 
or observed an increased risk of Pf infection in infants who had high levels of antimalarial IgG in 
cord plasma (13, 19, 21, 22). If Pf IgG levels during the first year of life reflect protection from 
Pf or are markers of infection warrant more investigation. 
Furthermore, fetuses in malaria-endemic areas can be exposed Pf Ags in utero (23–25), 
meaning that the first post-natal infection in some infants actually constitutes a secondary 
exposure to parasite Ags. Yet it is unclear, if infants exposed to Pf before birth generate a recall 
antibody response during the first infection after birth. Pf-specific IgG Abs have been detected in 
some newborns (26, 27) suggesting prenatal priming to Pf occurs, but it is unknown if the 
prenatal Ab response is accompanied by the production of Pf-specific memory B cells. A careful 
assessment of Pf IgM and IgG response patterns during the first post-natal infection in infants of 
women with well characterized placental Pf infection status can contribute in determining if B 
cell memory to Pf is generated in utero and what prenatal exposure-related factors are involved.  
The aims of the present study were to: 1) investigate the natural decline of maternal Abs 
to Pf Ags in a longitudinal cohort of Cameroonian infants, 2) determine if maternal Abs are 
associated with protection from malarial infections during the first year of life by examining Ab 
profiles of infants classified as resistant, intermediate and susceptible to malaria based on 
number of infections and time to first infection during the first year of life; and  3) explore if 
placental malaria (PM) and placental parasite density are associated with boosting of IgG and/or 
IgM levels in infants during their first Pf infection.  
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MATERIALS AND METHODS 
Study design  
The study was performed in the Ngali II locality situated about 40 km from the city of 
Yaoundé, Cameroon. The predominantly rural community has a total population of 
approximately 1,200 inhabitants and malaria transmission in the village was considered high as 
entomological inoculation rates (EIR) of up to 257 bites per person per year have been recorded 
(28). From May 2001 to November 2004, pregnant women were informed about the project and 
the newborns of women who signed informed consent forms were included as study participants. 
At enrollment, delivery information was recorded and placental samples were collected for 
diagnosis of PM. After birth, infants were monitored regularly during programmed visits at 7 
days, 6 weeks, 3, 4, 5, 6 8, 10 and 12 months of life. At each follow-up visit, infant peripheral 
blood samples were collected by finger prick and used for parasitological and Ab studies. 
Samples collected from 70 infants who were not lost from follow up before the 8
th
 month visit 
were included in analyses.  
To study the decline of maternal Pf Ab in the absence of infection, plasma and clinical 
data were obtained from 35 infants born and raised in Yaoundé, Cameroon, a low transmission 
area. The infants were recruited and followed as described above. Longitudinally-collected blood 
samples showed the infants were PCR-negative for malaria at all time points.  Thus, a total of 
105 infants in high and low transmission areas of Cameroon were included in the overall study.   
Parasitological studies 
Thick smears of placental intervillous space (IVS) blood were stained with Diff-Quick 
and visualized under a microscope. Histo-sections from placental biopsies, stored in 10% 
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buffered formalin, were prepared and stained with Hematoxylin-Eosin before microscopic 
examination. PM was defined as the presence of Pf parasites in IVS blood smear and/or in histo-
sections. Placental parasite density was considered low (PM-positive-low) if ˂median density of 
all PM-positive cases or high (PM-positive-high) if ≥ median.  
Pf infections during the first year of life were detected in peripheral blood samples of 
infants by microscopy and PCR.  PCR was performed by amplifying the 18S ribosomal subunit 
gene of Pf using primers and protocols that have been described previously (29, 30). 
Antibody studies 
 Abs to 5 Pf merozoite-stage Ags (MSP1, MSP2, MSP3, AMA1, EBA175), one ring-stage 
erythrocyte surface Ag (RESA), and 2 exo-erythrocytic-stage Ags (CSP and LSA1) were 
measured in infant plasma samples using a multiplex Luminex assay. The description of each Ag 
including the amount of Ag used to coat seroMAP bead surfaces is provided in Supplemental 
Table 1. Beads with distinct spectral addresses were used for each Ag. A bead mix containing 
100 of each Ag-coupled bead type per µL of PBS-1%BSA was made and 50 µL of the mix was 
added to 50 µL of diluted plasma                                                                                                                              
1/100 in PBS-1%BSA) in filter plate wells (Multiscreen BV, Millipore, Billerica, MA). After 
one hour of incubation on a 500-rpm shaker (Lab-line, Melrose Park, IL) in the dark at room 
temperature, the plate wells were washed 5 times with PBS-0.05% Tween 20 using a vacuum 
manifold (ZIP Plate Micro SPE plate, Millipore, Billerica, MA). Then, 0.1 mg (100 µL) of R-
phycoerythrin conjugated to the F(ab’) 2 fragment of goat anti-human IgG or to the F (ab’) 2 
fragment of donkey anti-human IgM (Jackson Immunoresearch, West Grove, PA) was added to 
each well. After 30 mins of incubation, the plates were washed again 5 times and the beads were 
resuspended in 100μl PBS-1%BSA. The plates were then read in the Liquichip M100 instrument 
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(Qiagen, Valencia, CA) which detected the spectral address of each bead type (hence 
corresponding Ag) and the median intensity fluorescence (MFI) of phycoerythrin (i.e., amount of 
Abs bound). Appropriate positive and negative controls were included on each plate 
Statistics 
 Based on the time from birth to first infection and the total number of times Pf was 
detected by PCR during the first year of life, the 70 infants in the high transmission birth cohort 
were categorized as shown in Fig. 1: resistant to Pf infections (no Pf infection occurred during 
the first five months of life, n = 16); intermediately resistant to Pf included babies with infections 
during the first 5 months but their total number of infections during the entire follow-up period 
was <5, n = 31); and susceptible to Pf (total number times infected ≥5). Baseline descriptive data 
were compared between the resistant and susceptible groups using Fisher’s exact test for 
categorical variables, such as percent PM-positive, and Student t test for continuous variables, 
such as birth weight (Table 1). Resistant and susceptible infants had similar baseline 
characteristics except that resistant infants were more likely to have been born to mothers with 
high placental Pf density than susceptible infants (p = 0.06). To determine if Ab levels in infants 
were markers of resistance or susceptibility to infection, average antibody levels at each 
timepoint were plotted for infants of each group and the profiles were compared with a focus on 
differences between the resistant and susceptible infants.  
Mathematical modeling was used to determine if Pf IgG and/or IgM levels during infancy 
were significantly boosted at first Pf infection and if PM status influenced the response.  A set of 
regression models capable of handling longitudinal outcomes and predictors were generated. The 
models were built using Ab levels tracked from day 7 of life to the time of first Pf infection or to 
the last follow-up visit if no infection had occurred. Antibody MFI was regarded as a count-type 
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repeated measure outcome variable in a predictive model that was based on generalized 
estimating equations (GEE), with first Pf infection as the predictor of primary interest.  
Adjustments were made for covariates, such as baseline Ab level, length of time from baseline to 
infection and for grouping variables such as PM status. Models were fitted for six different 
scenarios: no grouping variable, grouping by PM-positive/PM-negative, and by placental Pf 
density (PM-positive-low, PM-positive-high, PM-negative). The models containing grouping 
variables also included group interaction terms with first Pf infection. These models were fitted 
with log link function with AR-1 type correlation structure for specifying the correlation 
among repeatedly measured antibody levels. Note that the GEE approach estimates a marginal 
model that is robust against possible misspecification of correlation structure.    
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RESULTS 
Infant susceptibility to Pf infections 
Infants were divided into 3 groups based on the number of PCR-detected infections they had 
during the first year of life (Table 1). No significant differences were found between the groups 
in any of the parameters evaluated, including months of follow-up, except for placental Pf 
density at birth. Overall, 60% of the PM-positive mothers who gave birth to resistant infants had 
high placental parasitemia compared to only 8% of mothers whose infants were highly 
susceptible to malaria. Thus, having a mother with high placental parasitemia may be an 
advantage for infants.   
Decline of maternal Pf IgG 
 The natural decline of maternal Ab in the absence of malaria infection during the first 
year of life was Ag-dependent. IgG waned, reaching its lowest levels at 6 months of age for 
MSP1 and at 8–12 months for EBA175 and AMA1 (Fig. 2, low transmission panels). Infants 
were born with minimal amounts of Ab to MSP2 that were gone by 3 months of age.    
Acquisition of Pf IgG through the first year of life 
Ab levels for infants of the susceptible and resistant high transmission groups were 
similar at birth (Fig. 2) and declined at similar rates among the infants. A comparison of results 
Pf prevalence (in Fig. 1) and Ab profiles (Fig. 2) showed that Ab to MSP1 IgG increased in 
parallel with infection. For example, MSP1 IgG levels begin rising at 6 months, 4 months, and 3 
months for resistant, intermediate and susceptible infants, respectively, corresponding to 
timepoints where the prevalence of infections increased in the corresponding groups. 
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Collectively, there was no evidence that maternal MSP1 IgG or IgG to the other Ags was 
associated with protection from infection. 
 On the other hand, IgG to EBA175 and AMA1, declined steadily in resistant, 
intermediate and susceptible infants, even though the infants became infected with malaria 
multiple times. The rate of decline of EBA175 IgG was not related to amount present at birth, as 
infants in the all 3 groups lost their maternal IgG until 10 months of age at a rate like that of 
unexposed infants. MSP2 maternal IgG declined faster than Ab to EBA175 or AMA1 reaching 
lowest levels at about 4 months. Thereafter, MSP2 IgG remained low until about age 8 months, 
when the infant began producing its own MSP2 IgG. The MSP3 profiles were similar to those of 
MSP2, but the MFIs were lower (supplemental Fig. 1). Compared to all the other Ags, very little 
or no IgG to RESA, CSP and LSA were passively acquired by infants from their mothers.  
 Of great interest, Ab levels to Ags other than MSP1 did not increase in parallel with 
infection (compare Fig. 1 and Fig. 2). Thus, it appears that some of the babies did not produce 
significant amounts of Ab to most of the Ags upon repeated infection during the first year of life.   
Antibody response at first post-natal infection 
 Using GEE longitudinal regression models, significant boosting of IgG to the two the 
MSP1 variants, MSP2-FC7 and to LSA1, but not the other Ags was observed at the first 
infection (Fig. 3A). No interaction effect of being born from a PM-positive mother and 
experiencing the first Pf infection during infancy was found (Fig 3B).  However, when 
interaction effects with placental parasite density were examined, infants of PM-positive-high 
had a strong boost in their IgG levels to MSP1 3D7 and MSP1-FVO; whereas, this effect was 
absent in infants born to PM-positive-low mothers or PM-negative mothers (Fig. 3C and D). 
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Taken together, infants made IgG to MSP1 during their first infection, and the boosting effect 
was higher if they were born to mothers with high placental parasite density. 
 The longitudinal models were also applied for IgM to MSP1-3D7 and MSP1-FVO, and to 
EBA175. At the first occurrence of infection, IgM levels for the two MSP1 proteins were also 
boosted in addition to IgG (Fig. 4A). Interestingly, the infants made IgM, and not IgG, to 
EBA175 showing that the Ab response to EBA175 at first infection was a primary response. 
Again, general PM and low placental parasite density did not have significant effect on IgM or 
IgG levels for any of the tested Ags. However, PM-positive-high infants had a significant boost 
of IgG and not IgM to the MSP1 variants. Therefore, infants born to PM-positive-high mothers 
generate a secondary Ab response during the first Pf infection after birth.  
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DISCUSSION  
 The study extensively profiled Ab levels to broad set of Pf Ags during the first year of 
life and used robust modeling methods to evaluate Ab responses during the first post-natal 
infection with attention to prenatal exposure to Pf. Important findings include: 1) maternally 
acquired Pf IgG are not correlates of resistance to Pf infections during the first year of life; 2) the 
pattern of acquisition of Abs to Pf during the first year of life in general and specifically during 
the first post-natal infection is Ag-dependent; and 3) infants born to PM-positive mothers with 
high placental parasite density are more likely to mount a secondary recall Ab response to Pf 
than infants born to PM-negative or PM-positive mothers with low placental Pf density. 
 The hemochorial architecture of the human placenta and its Fc-neonatal receptors allow 
the efficient transfer of maternal IgG to the fetus, but the effective role of maternal IgG in 
protecting the infant from malarial infections is currently under debate. Results of the current 
study show that infants who are resistant and susceptible to Pf infections have similar baseline 
levels of maternal IgG to Pf Ags. Therefore, serologically measured levels of maternal Ab in the 
infant do not predict resistance or susceptibility to infections. The data corroborate with results 
from a Ghanaian cohort that showed no association between IgG to MSP-1, MSP-2, AMA-1, and 
RESA in newborn plasma and resistance to Pf infection during infancy (22).  
Still, a protective role of maternal antibodies cannot be completely ruled out particularly 
during the first 3 months, since the prevalence of Pf infections before 3 months was significantly 
lower than age-related prevalence after 3 months, even in susceptible infants. Perhaps the levels 
of functional maternal Abd, and not total Abs are better correlates of resistance to Pf in the 
infants, as contrasting profiles of Abs measured by serology and functional assays have been 
reported in a Kenyan cohort (31). It is also possible that relative protection from malaria during 
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the first 3 months is accounted for by multiple factors mentioned in previous reviews (14, 15). 
These other factors include: fetal hemoglobin which constitutes the high percentage of infant 
hemoglobin during the first two months of life and can inhibit intra-erythrocytic growth of 
parasites (32) and breast-feeding which deprives the parasite of para-aminobenzoic acid (pABA). 
pABA is an essential nutrient for parasite growth but breast milk naturally contains little or no 
pABA.  Reduced exposure to Pf during the first 3 months of life can also be due to the fact that 
younger babies were culturally better taken care of and were better covered with clothes than 
older babies in the Ngali II community, thus the older infants will be more susceptible to 
mosquito bites. Maternal Abs together with these factors may contribute to reduced prevalence 
of malaria infections during the first couple of months but there remains no solid evidence that 
maternal Abs are correlates of protection from malaria during the first year of life. 
The overall pattern of acquisition of Pf Abs was unique for each Ag, but two patterns 
stood out. First, the Ab acquisition pattern of MSP1 antibodies very well mirrored the prevalence 
of Pf at each time-point. Infants tend to make IgG first to MSP1 before making IgG to other Ags. 
In contrast, the profiles for AMA1 and particularly EBA175 were different, characterized by a 
steady drop of maternal IgG up to age 8–12 months irrespective of number of infections the 
infant receives. MSP2 pattern was similar but a faster drop of maternal IgG was observed. The 
infants did not seem to actively produce anti-AMA1 and EBA175 IgG in response to many 
infections. A possible explanation for the differential dynamics of infant Ab profiles between 
MSP1 and EBA175 could be that the higher and longer lasting levels of maternal EBA175 IgG 
exert an negative feedback effect on the infant’s EBA175-specific B cells via inhibitory Fc 
gamma receptor 2b (FcγRIIb) (33). Another reason could be related to in utero priming. Because 
MSP1 is the most abundant Ag in the merozoite surface, fetuses will hypothetically be more 
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exposed and primed to MSP1 than EBA175 or AMA1 which are proteins found in relatively 
small amounts in the micronemal regions of the merozoite. Therefore, infants would more likely 
to generate a recall response to MSP1 early during infancy than to EBA175 or AMA1. In 
addition, it was observed that infants made IgM and not IgG to EBA at their first infection 
supporting the idea that post-natal response to EBA175 is a primary immune response and not a 
secondary recall response. Thirdly, MSP1 could be more immunogenic than EBA175 or AMA in 
infants. However, Ab levels to AMA1 are usually higher than MSP1 levels in older children and 
adults (34), thus it remains puzzling why MSP1 will be more immunogenic infants. In all, the 
differential patterns of antibody acquisition should be taken into consideration in the design of 
anti-malarial vaccines that target infants. 
A principal finding of the study is that the MSP1 IgG response at the first Pf infection 
after birth is modified by placental parasite density. The fact that a boosting of MSP1 IgG at first 
infection was seen only in infants born to PM-positive women with high placental parasite 
density and the finding that MSP1 IgG boosting in the PM-positive-high group was not 
accompanied by IgM production, strongly suggest that secondary Ab responses MSP1 are 
generated during primary post-natal infection if exposure to high, and not low, amounts of Ag 
occurred before birth. The findings provide indirect evidence that memory B cells can be 
generated in utero and persists through early to mid-infancy. As demonstrated in in vitro models 
with mouse transgenic T cells, high Ag dose is necessary for T helper cells to escape suppression 
by T regulatory cells (T-regs) (35). Given that fetal T cells are biased towards T-regs (36–38), it 
is plausible that the threshold antigen dose needed to activate fetal T effector cells will be high in 
utero. Since cognate interaction with activated T cells is required for B-cell activation and 
migration into the germinal centers for differentiation into memory B cells and long-lived plasma 
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cells (39), Ag amount in utero may also predict if antigen-specific memory will be generated. 
Although germinal centers are scarcely identified in lymphoid tissue of stillbirths (40), somatic 
hypermutations have been detected in preterm babies after exposure to environmental Ags (41), 
suggesting that with the right threshold of exposure, germinal centers and hence memory B cells 
could also be made in utero. 
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Figure 1. Classification of infants. Age-specific prevalence of Pf infections detected by PCR are 
shown for a total of 70 infants living in high Pf transmission village of Ngali II, Cameroon. The 
infants were further divided into 3 groups based on susceptibility to Pf infections during the first 
year of life. Resistant infants experienced no Pf infections until age 6 months (n=16), As from 
age 3 months, 70–90% of susceptible infants (n=23) and 30–60% of intermediate infants (n=31) 
were positive for Pf every month. The low transmission controls (n=35) from the city of 
Yaounde were not positive for Pf any time during the first year of life. 
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Table 1. Description of infants from the high transmission birth cohort of Ngali II 
Description Resistant 
infants 
Intermediate 
infants 
Susceptible 
infants 
P 
Value
*
 
Number of infants 16 31 23 n/a 
Duration of follow-up (months from birth) 11.4±1.4 11.1±2.4 11.4±1.5 0.93 
% residing at the outskirts of Ngali II village  56% 61% 52% 1.0 
% born during the rainy season 63% 42% 48% 0.52 
Gestational age at birth (weeks) 39.5±1.9 39.3±2.0 39.0±2.2 0.51 
Birth weight (grams) 3292±456 3099±501 3221±479 0.68 
Number with available placental samples 12 29 18 n/a 
% Placental malaria (PM) positive 42% 41% 61% 0.46 
% PM-positive with high placental Pf density 60% 33% 8% 0.06 
*
Resistant versus susceptible 
n/a, not applicable 
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Figure 2. Kinetics of circulating IgG to Pf MSP1, EBA175, AMA1 and MSP2 during the first 
year of life. Antibody levels at each time point are represented as mean and SEM. Similar IgG 
patterns were observed for variants of the same antigen, so data are shown for only one variant of 
each antigen (MSP1-FVO, AMA1-FVO and MSP2-FC27).  
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Figure 3. Assessment of Pf IgG boosting at first infection. GEE longitudinal regression models 
were used to determine if antibody levels at first infection were significantly higher than 
preceding visit level. Adjustments were made for covariates including baseline IgG at the start of 
infant follow up and time from birth. Each panel shows the effect of first Pf infection or the 
interaction between the occurrence of first infection and a PM subgroup (PM-positive, presence 
of Pf parasites in the placenta at birth; PM-positive-low, placental parasite density <median; PM-
positive-high, placental parasite density>median). The shaded area shows area where the 
regression coefficients are positive and significant. The antibodies to antigens within the shaded 
area were significantly boosted 
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Figure 4. Assessment of Pf IgG and IgM boosting at first infection. In addition to IgG, IgM 
boosting was assessed for MSP1-3D7, MSP1-FVO and EBA175. 
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Supplementary table 1. Recombinant and synthetic antigens used in antibody assays 
Antigen Strain  
or sequence 
Type Expression  
system 
Antigen amount used per 
million beads  
MSP142 FVO Recombinant Escherichia coli 1 µg 
MSP142 3D7 Recombinant Escherichia coli 1 µg 
MSP2 FC27 Recombinant Escherichia coli 1 µg 
MSP2 3D7 Recombinant Escherichia coli 1 µg 
MSP3 3D7, C-Terminal Recombinant Escherichia coli 0.2 µg 
AMA1 FVO Recombinant Yeast cells 1 µg 
AMA1 3D7 Recombinant Yeast cells 1 µg 
EBA175  Region II Recombinant Yeast cells 0.2 µg 
RESA  [EENV]5-BSA Synthetic n/a 2.5 µg 
CSP  [PNAN]5-BSA Synthetic n/a 2.5 µg 
LSA1 -BSA Synthetic n/a 4 nmol 
Source of antigens: 
--MSP1, MSP2 and AMA1 provided by Carole A. Long, Laboratory of Malaria and Vector 
Research, National Institute of Allergy and Infectious Diseases (Rockville, MD) 
--EBA175 obtained from Science Applications International Corp. (Frederick, MD) 
--RESA and CSP synthesized by AnaSpec, Inc. (San Jose, CA) 
--LSA peptide synthetized by Genosys-Sigma-Aldrich (Saint Louis, MO) 
n/a, not applicable 
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Supplemental figure 1. Kinetics of circulating IgG to Pf MSP3, RESA, CSP and LSA1 during 
the first year of life. 
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CHAPTER 5 
DISCUSSION 
The burden of malaria is disproportionately high in children and pregnant women. In 
2015, 69% of 438,000 malaria-related deaths reported worldwide occurred in children less than 5 
years old. Annually, about 30 million pregnant women are at risk of malaria, and infections 
during pregnancy can lead to severe complications for the mother and her baby. Besides the well 
documented malaria-associated pregnancy complications such as preterm delivery and low birth 
weights, in endemic areas, it is now being recognized that fetuses of Plasmodium falciparum 
(Pf)-infected women can be exposed to Pf in utero. The dynamics of prenatal Pf exposure and its 
repercussions on the health of infants after birth are not well understood.  
Data from immunological studies provide some explanation for the overly high malaria 
burden in children and pregnant women. Immunity to malaria is never sterile, but significant 
protection from severe forms of malaria and high parasite loads can be attained by individuals in 
high transmission areas after years of repeated exposures to the parasite. Thus, acquired 
immunity to malaria is more robust in adults compared to children, resulting in the latter being 
more susceptible to Pf infections and severe disease. However, most immuno-epidemiological 
studies on malarial immunity in children, or lack of, have focused on children aged 2 to 10 years. 
Little is known about how infants acquire immunity to malaria during their first year of life. 
Like many adults in malaria-endemic areas, women of child-bearing age have high levels 
of antibodies to Pf blood-stage antigens but these women face novel challenges in combating Pf 
parasites when they become pregnant for the first time. In pregnant women, Pf-infected 
erythrocytes express a distinct surface protein, VAR2CSA, which binds to CSA on placental villi 
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and allows infected erythrocytes to accumulate in perivillous spaces. This condition, known as 
placental malaria (PM), is the hallmark pathologic feature of malaria in pregnancy. Research on 
immunity to PM has advanced greatly over the past decade as anti-VARCSA antibodies, that 
inhibit placental sequestration of infected erythrocytes, have been identified and the natural 
acquisition of these antibodies during the course of pregnancy and over successive pregnancies 
has been extensively studied. PM also facilitates exposure of the fetus to Pf antigens, but 
relatively little is known about the development of antibody responses in utero. 
Taken together, the threat of malaria to maternal and child health is undisputed and much 
research effort has been invested into understanding the determinants of susceptibility to 
infection and the process of acquiring immunity to Pf in pregnant women and children. But two 
developmental periods during pregnancy and childhood have received less research attention, 
i.e., the fetal period and the first year of life. The present dissertation uniquely and specifically 
focused on Pf exposure and induced antibody responses in fetuses and infants. If immune 
responses are mounted against Pf in utero, post-natal acquisition of immunity to Pf will 
potentially be influenced by the nature of the prenatal responses. A good understanding of the 
process of acquisition of immunity to Pf in infants is necessary in the design of anti-malarial 
vaccines that will be efficient when administered to this age group.  
There are a few reasons why research progress on fetal and infant immune responses to 
Pf has been slow. First, fetal samples are difficult to obtain. Fetal tissue is not accessible for 
routine sampling during gestation. Percutaneous umbilical cord blood sampling, also referred to 
as cordocentesis, can be performed before birth, but this procedure is invasive and sometimes 
induces premature labor. Besides, many health care providers in countries where malaria is 
endemic do not have the skills to perform such specialized procedures. Therefore, much of what 
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is known about fetal responses to Pf emanate from studies done using umbilical cord blood 
collected at birth. These studies have demonstrated Pf antigen-driven cord blood T cell 
proliferation and cytokine production in vitro, Pf-specific IgM in cord plasma and IgG in vitro, 
all pointing to the possibility of T- and B-lymphocyte priming to Pf in utero. However, because 
these studies were conducted in full term newborns, it was not clear when during fetal 
development immune priming occurred and if the quantity or quality of the prenatal immune 
response to Pf was influenced by gestational age. Some of the research conducted as part of this 
dissertation constitutes pioneer work of fetal antibody responses to Pf at gestational ages ranging 
from 20 weeks to 40 weeks. The work was possible because of the availability of a unique and 
impressive archive of samples collected from Yaoundé, Cameroon at a period when local malaria 
transmission and the prevalence of preterm birth were a lot higher than are today. Between 1998 
and 2001, 34% of deliveries in Yaoundé were preterm, i.e., birth before 37 complete weeks of 
gestation, but in the years 2014 and 2015 the prevalence dropped to about 12% (Tassi Yunga et 
al., unpublished).  
Second, the advancement of scientific knowledge on immune responses to Pf during the 
fetal period and during infancy have been hindered by populist views and dogmas that are either 
not evidence-based or are based on archaic scientific findings. For example, it was widely 
believed that fetuses cannot mount any significant effector responses to foreign antigens because 
of a bias towards tolerance in utero and that infants do not need to mount responses to 
environmental antigens because they are protected by passive immunity acquired 
transplacentally or from breast milk. Our current studies question some of these stereotypes as 
we investigated, among other things, the components, timing and amount of exposure to Pf in 
utero; if preterm newborns, including some extremely premature (20–28 weeks) newborns 
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exposed to Pf in utero made antibodies to Pf; if the amount, breadth and isotype of these 
antibodies were different from that of exposed term newborns; and if maternal Pf-specific IgG in 
cord blood offer any protection from Pf infections during the first year of life. We also 
investigated associations between the amount of prenatal Pf exposure and post-natal outcomes, 
such as the time to first infection and antibody response profile at that first infection.  
The current studies confirm that the developing fetus can be exposed to whole parasites 
and parasite products including DNA, secreted proteins and antigens bound to Pf IgG as immune 
complexes (IC). Intact parasites, free parasite DNA and proteins are thought to be transported 
across the placenta via microabrasions that may be induced by PM. Pf-DNA and Pf-
glycosylphosphatidylinositol (GPI) – an endotoxin-like anchor for some Pf antigens – are 
pathogen-associated molecular patterns (PAMP). Therefore, both Pf antigens and PAMPs that 
respectively provide the first and second signals needed for efficient T helper cell activation are 
transferred across the placenta into the fetal circulation. Since antigen-presenting cells and 
lymphocytes have previously been identified in fetal lymphoid organs from 10–12 weeks of 
gestation, and pattern recognition receptors for Pf PAMPs (i.e., TLR9 for DNA and TLR1/2, 
TLR4, TLR2/6 for GPI) have been detected in prenatal tissue, proof that Pf antigens and PAMPs 
are present in cord blood suggests T- and B-cell sensitization can occur to Pf in utero.  
With regards to which form of Pf exposure is predominant in utero, our data show that 
while intact parasites that contain multiple Pf antigens and PAMPs are rarely detected in cord 
blood (1 case out of 70 newborns) up to 25% of Cameroonian newborns (169 out of 682) had 
immunologic evidence (Pf IgM in cord blood) of exposure to one or more Pf antigens in utero. 
This suggests that exposure to individual antigens in the form of IC could be the primary 
mechanism by which fetuses encounter Pf in utero; however, there was absolutely no association 
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between being positive for Pf IgM and having Pf IC in cord blood, which brings into doubt the 
relevance IC as a mechanism of exposure to Pf. On the other hand, 27% (46 out of 169) of the 
cord IgM positive newborns recognized a wide breadth of Pf antigens indicating exposure to 
multiple antigens as are present in intact infected erythrocytes. Also, Pf was more commonly 
detected in cord blood by PCR than by microscopy, indicating that sub-microscopic amounts of 
Pf parasites were present in cord blood. Therefore, intact infected erythrocytes cannot be ruled 
out as a major source of Pf antigens for priming in utero. The fact that neonates born as early as 
22 weeks were positive for Pf IgM to all tested antigens shows exposure to Pf parasites can occur 
any time from the second trimester through full term and induce a B cell responses. 
Our data also demonstrate for the first time that placental parasite density is a proxy for 
the overall level of maternal and fetal exposure to Pf during pregnancy. It is impossible to 
directly quantify Pf exposure in the fetus throughout pregnancy.  Thus, indirect measures of 
parasite load during pregnancy, such as number of times pregnant women were positive for Pf 
and average peripheral parasite density, were used.  We demonstrated that frequent infections 
with high density parasitemia during the second and third trimesters are associated with higher 
parasite loads in the placenta at delivery, which in turn, is associated with a higher likelihood of 
cord blood parasitemia. This is a novel finding and it implies that quantification of parasite load 
in the placenta at birth provides insight on the level of exposure to Pf that newborns encounter 
during gestation. 
Limitations in the number of circulating lymphocytes and in the diversity B cell receptor 
repertoire have been previously reported in preterm babies, but restricted diversity was not 
reflected in our Pf antibody data.  Fetal antibody responses to Pf were not restricted in amount or 
in breadth for preterm newborns compared to full term newborns. Still, it is possible that 
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potential differences in breadth of IgM response were not detected in the present studies because 
of the small number of Pf antigens used to screen cord plasma for IgM. Nonetheless, we found 
that the ability of at least one fetal B cell clone to be primed for Pf antibody production in utero 
is not altered during early to mid pregnancy. Remarkably, the proportion of newborns that made 
IgM to Pf in utero decreased with increasing gestational age. The observed trend was most likely 
due to class-switch from Pf-IgM to Pf-IgG production since lymphocytes of term newborns 
overwhelmingly secreted Pf IgG in vitro.  
The finding of antibody class-switching in utero suggests, but does not confirm, that Pf-
specific memory B cells are generated in exposed fetuses. The Pf IgG may have been produced 
by short-lived plasma cells which have undergone extrafollicular class-switch recombination. 
Yet, it was fascinating to find a secondary antibody response to the MSP1 antigen at the first 
infection after birth in some infants, which is indirect evidence that MSP1-specific memory B 
cells were produced in utero and persisted into the post-natal period. Studies specifically aimed 
at identifying polyclonal and antigen-specific memory B cells in cord blood are needed to 
provide direct evidence of Pf-memory B cell generation in utero. We have received a pilot grant 
via University of Hawaii Centers of Biomedical Research Excellence (COBRE) and the New 
Mexico IDeA Networks of Biomedical Research Excellence (NM-INBRE) for a study of the B 
cell transcriptome of Cameroonian newborns exposed to Pf in utero, which may provide 
information on Pf-induced changes in fetal B cells. RNA obtained from sorted B cells of PM-
positive and PM-negative newborns as well as North American control newborns will be deep 
sequenced for differential gene expression analyses. 
With regards to our first year of life antibody studies, we have demonstrated that not all 
passively acquired maternal Pf IgG disappear by 6 months of life and that maternal IgG are not 
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correlates of protection from infection as previously assumed. The pattern of decline of Pf IgG 
during the first year of life was not identical for all Pf antigens. While levels of maternal IgG to 
many merozoite antigens completely waned before 6 months, maternal IgG to EBA175 and 
AMA1 remained in infant circulation until 8–12 months of life. On the other hand, infants 
typically produced IgG to MSP1 from their first postnatal infection, but little or no IgG to 
EBA175 and AMA1 were produced by infants in response to infections. We speculate that 
persistent maternal IgG to AMA1 and EBA175 may be inhibiting active acquisition of IgG to 
these antigens by the infant. The differential pattern of acquisition of antibodies to Pf antigens 
may have significant translational impact on vaccine designs. AMA1 and EBA175 are vaccine 
candidates, but based on the present data, administration of a vaccine based on these two 
antigens during the first year of life may not induce any active immune response because not 
much natural immunity to these antigens is acquired by infants in endemic areas 
Finally, the current studies contribute significantly to the field of fetal origins of disease 
susceptibility. Prior to our work, many authors had repeatedly observed that offspring of PM-
positive women had higher odds of becoming infected with Pf than offspring of women who did 
not have PM, but the underlying mechanisms were unclear. Our studies present maiden findings 
that the amount of exposure to Pf, reflected by placental parasite density modifies PM-related 
risk malaria in infants. The infants that were most at risk of experiencing a short time to first 
postnatal infection were those whose mothers had relatively low placental parasite densities. 
Infants of high PM parasitemia mothers had similar, and in some instances, better outcomes than 
infants of PM-negative mothers. Our explanation for this finding is that, in the intrauterine 
environment where T regulatory cell suppression of T effector functions is high, a threshold 
amount of Pf antigen (and PAMPs) is required for T helper cells to overcome T-reg suppression 
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and become sensitized to Pf. Our additional findings that PM-positive-high and not PM-positive-
low infants had a recall antibody response to MSP1 during the first post-natal infection 
corroborate with an antigen threshold requirement for activation of fetal T and B lymphocytes. 
Overall, the key take-home messages from these studies are that fetuses are not 
immunologically naïve to Pf but are capable of mounting Pf-specific responses in utero and the 
impact of prenatal exposure to Pf on post-natal malaria susceptibility depends on the amount of 
malarial antigen exposure in utero – low dose antigen exposure having a worse outcome than 
relatively high dose exposure. In translational terms, this means that malaria control measures 
that reduce placental parasite density, but do not prevent PM, will inadvertently increase the risk 
to Pf infections after birth. The currently used regimen for intermittent preventive treatment of 
malaria in pregnancy (sulfadoxine-pyremethamine) is reportedly ineffective in some parts of 
Africa in clearing placental parasites because of rising drug resistance. Based on our findings, 
health policy makers should consider replacing sulfadoxine-pyremethamine with more effective 
drugs in areas where resistance is being reported to prevent low antigenic exposure of fetuses. 
The present dissertation does not exhaustively investigate early immune responses to Pf. 
Looking forward, there are interesting research questions that could be addressed. Because 
infants acquired antibodies to MSP1 before making antibodies to other Pf antigens, it will be 
important to further investigate the fine specificity of MSP1 IgG in infants. Not all IgG to MSP1 
are functionally important in controlling Pf parasites – some of the MSP1 IgG inhibit erythrocyte 
invasion by merozoites, while others block this inhibitory process, and other MSP1 IgG are 
simply neutral. Also, in some of our side studies of antibody profiles in individuals aged 5–80 
years old, we found an age-related pattern of acquisition of Pf antibodies which is opposite to the 
pattern during the first year of life. That is, in children 5–10 years old, high levels of IgG to 
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AMA1 and EBA175, comparable to adult levels, were detected, while MSP1 IgG were relatively 
low in this age group and continued to rise with age up to 15–20 years. Therefore, in the age gap 
of 1–5 years, it is unclear at what point EBA175 and AMA1 IgG production overtake MSP1 IgG 
production and its bearing to age-dependent changes in childhood susceptibility to malaria. 
Furthermore, children of the 2001–2005 birth cohort are currently in their teenage years. It will 
be important to investigate if the differences in immune response to Pf and susceptibility to 
malaria seen during the first year of life in relation to prenatal exposure persist through late 
childhood.  
 
 
